Document:

EX-10.16

 Exhibit 10.16 

CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[***]”, HAS BEEN EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND
(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 
 EXECUTION VERSION

 WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 

and 
 YUMANITY
THERAPEUTICS, INC. 
 And 

YUMANITY HOLDINGS LLC 

TANGIBLE PROPERTY AND EXCLUSIVE PATENT LICENSE AGREEMENT 

Dated 
 February 4,
2016 
  

 TABLE OF CONTENTS 

 

					
	 R E C I T A L S
	  	 	1	 
		
	 1. Definitions
	  	 	4	 
		
	 2. Grant of Rights
	  	 	10	 
		
	 3. Company Diligence Obligations
	  	 	13	 
		
	 4. Royalties and Payment Terms
	  	 	15	 
		
	 5. Reports and Record keeping
	  	 	20	 
		
	 6. Patent Prosecution
	  	 	23	 
		
	 7. Infringement
	  	 	24	 
		
	 8. Indemnification and Insurance
	  	 	27	 
		
	 9. Representations or Warranties
	  	 	29	 
		
	 10. Assignment
	  	 	30	 
		
	 11. General Compliance with Laws
	  	 	31	 
		
	 12. Termination
	  	 	32	 
		
	 13. Dispute Resolution
	  	 	34	 
		
	 14. Miscellaneous
	  	 	35	 
		
	 APPENDIX A
	  	 	40	 
		
	 APPENDIX B
	  	 	41	 
		
	 APPENDIX C
	  	 	42	 
		
	 APPENDIX D
	  	 	43	 

 WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 

EXCLUSIVE PATENT LICENSE AGREEMENT 

This Agreement, effective as of February 4, 2016 (the “EFFECTIVE DATE”), is between the Whitehead
Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Yumanity Therapeutics, Inc.
(“COMPANY”), a Delaware corporation, and solely for the purpose of Section 4.1(i) Yumanity Holdings LLC (“PARENT”), a Delaware limited liability company, both with a principal office at 790 Memorial Drive, Suite
2C, Cambridge, MA 02139. WHITEHEAD and COMPANY are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

R E C I T A L S 

WHEREAS, WHITEHEAD is the owner of certain WHITEHEAD PATENT RIGHTS listed in Appendix A to this Agreement, relating to WHITEHEAD Case No.
[***]; WHITEHEAD Case No. [***]; WHITEHEAD Case No. [***]; WHITEHEAD Case No. [***]; WHITEHEAD Case No. [***]; and WHITEHEAD Case No. [***]. The WHITEHEAD PATENT RIGHTS were
co-developed by Dr. Susan Lindquist as a Howard Hughes Medical Institute (“HHMI”) employee at her laboratory at WHITEHEAD, and has the right to grant licenses under said WHITEHEAD PATENT RIGHTS,
subject to a royalty-free, nonexclusive, nontransferable license to practice the WHITEHEAD PATENT RIGHTS reserved by the United States Government and subject to a paid-up, irrevocable license to HHMI for
research purposes, with no right to assign or sublicense; 
 WHEREAS, The University of Chicago (“UC”) owns certain UC PATENT
RIGHTS listed in Appendix A to this Agreement, relating to WHITEHEAD Case No. [***] and WHITEHEAD Case No. [***]. The UC PATENT RIGHTS were developed by Dr. Susan Lindquist while she was an HHMI employee at her laboratory at UC,
and UC has the right to grant licenses under said UC PATENT RIGHTS subject to a royalty-free, nonexclusive nontransferable license to practice the UC PATENT RIGHTS reserved by the United States Government and subject to a paid-up, irrevocable license to HHMI for research purposes, with no right to assign or sublicense; 

WHEREAS, UC has authorized WHITEHEAD to act as UC’s sole and exclusive agent for the purposes of licensing the UC PATENT RIGHTS and has
authorized WHITEHEAD to enter into this Agreement on its behalf; 

  
 1 

 WHEREAS, WHITEHEAD and the University of Washington (“UW”) are the joint owners of
certain WHITEHEAD/UW PATENT RIGHTS listed in Appendix A of this Agreement, relating to WHITEHEAD Case No. [***]. WHITEHEAD and UW have the right to grant licenses under said PATENT RIGHTS subject only to a royalty-free, nonexclusive
nontransferable license to practice the WHITEHEAD/UW PATENT RIGHTS reserved by the United States Government; 
 WHEREAS , UW has entered
into a Joint Invention Administration Agreement, effective July 15, 2015, that authorized WHITEHEAD to act as its sole and exclusive agent for the purposes of licensing the WHITEHEAD/UW PATENT RIGHTS and has authorized WHITEHEAD to enter into
this Agreement on its behalf; 
 WHEREAS, WHITEHEAD and the Curators of the University of Missouri (“UM”) are the owners of
certain WHITEHEAD/UM PATENT RIGHTS listed in Appendix A of this Agreement, relating to WHITEHEAD Case No. [***]. WHITEHEAD and UM have the right to grant licenses under said WHITEHEAD/UM PATENT RIGHTS subject only to a royalty-free,
nonexclusive, nontransferable license to practice the WHITEHEAD/UM PATENT RIGHTS reserved by the United States Government; 
 WHEREAS, UM
has authorized WHITEHEAD to act as its sole and exclusive agent for the purposes of licensing the WHITEHEAD/UM PATENT RIGHTS and has authorized WHITEHEAD to enter into this Agreement on its behalf; 

WHEREAS, WHITEHEAD and the Massachusetts Institute of Technology (“MIT”) are the owners of certain WHITEHEAD/MIT PATENT RIGHTS
listed in Appendix A of this Agreement, relating to WHITEHEAD Case No. [***]. The WHITEHEAD/MIT PATENT RIGHTS were co-developed by Susan Lindquist at her laboratory at WHITEHEAD as an employee of HHMI,
and WHITEHEAD and MIT have the right to grant licenses under said WHITEHEAD/MIT PATENT RIGHTS subject to a royalty-free, nonexclusive , nontransferable license to practice the WHITEHEAD/MIT PATENT RIGHTS reserved by the United States Government and
subject to a paid-up, irrevocable license to HHMI for research purposes , with no right to assign or sublicense; 

WHEREAS , MIT has entered into a Joint Invention Administration Agreement, effective November 7, 2013, that authorized WHITEHEAD to act as its
sole and exclusive agent for the purposes of licensing the WHITEHEAD/MIT PATENT RIGHTS and has authorized WHITEHEAD to enter into this Agreement on its behalf; 
  

  
 2 

 WHEREAS, WHITEHEAD and The Arizona Board of Regents on behalf of the University of Arizona
(“ARIZONA”) are the owners of certain WHITEHEAD/ARIZONA PATENT RIGHTS listed in Appendix A of this Agreement, relating to WHITEHEAD Case No. [***]. The WHITEHEAD/ARIZONA PATENT RIGHTS were co-developed by Susan
Lindquist as an HHMI employee at WHITEHEAD, and WHITEHEAD and ARIZONA have the right to grant licenses under said WHITEHEAD/ARIZONA PATENT RIGHTS subject only to a royalty-free, nonexclusive , nontransferable license to practice the
WHITEHEAD/ARIZONA PATENT RIGHTS reserved by the United States Government and subject to a paid-up, irrevocable license to HHMI for research purposes, with no right to assign or sublicense; 

WHEREAS, ARIZONA has authorized WHITEHEAD to act as its sole and exclusive agent for the purposes of licensing the WHITEHEAD/ARIZONA PATENT
RIGHTS and has authorized WHITEHEAD to enter into this Agreement on its behalf; 
 WHEREAS, WHITEHEAD and Pfizer, Inc. (“PFIZER”)
are the joint owners of certain WHITEHEAD/PFIZER PATENT RIGHTS listed in Appendix A of this Agreement, relating to WHITEHEAD Case No. [***]. WHITEHEAD has the right as a joint owner to grant licenses under said PATENT RIGHTS {US only} subject
only to a royalty-free, nonexclusive, nontransferable license to practice the WHITEHEAD/PFIZER PATENT RIGHTS reserved by the United States Government; 

WHEREAS, WHITEHEAD desires to have the WHITEHEAD PATENT RIGHTS, the WHITEHEAD/UW PATENT RIGHTS, the WHITEHEAD/UM PATENT RIGHTS, the
WHITEHEAD/MIT PATENT RIGHTS, the WHITEHEAD/PFIZER PATENT RIGHTS, the WHITEHEAD/ARIZONA PATENT RIGHTS and the UC PATENT RIGHTS (collectively, the “PATENT RIGHTS” as further defined below) developed and commercialized to benefit the public
and is willing to grant a license thereunder; and 
 WHEREAS, equity received pursuant to this Agreement shall satisfy WHITEHEAD’s
policy on equity sharing as stated in Appendix 6.4 of the Faculty Guide “Policy on Equity Received by Faculty or Professional Staff Being Shared with the Institute”; 

WHEREAS, COMPANY has represented to WHITEHEAD, to induce WHITEHEAD to enter into this Agreement, that COMPANY shall commit itself to a
diligent program of exploiting the PATENT RIGHTS and TANGIBLE PROPERTY so that public utilization shall result therefrom; and 
 WHEREAS,
COMPANY desires to obtain a license under the PATENT RIGHTS and TANGIBLE PROPERTY upon the terms and conditions hereinafter set forth. 

NOW, THEREFORE, WHITEHEAD and COMPANY hereby agree as follows: 

  
 3 

 1. DEFINITIONS 

1.1 “AFFILIATE” means any legal entity (such as a corporation, partnership, or limited liability company) that directly or
indirectly controls, is controlled by or is under common control with, COMPANY. For the purposes of this definition, the term “control” means (i) beneficial ownership of at least fifty percent (50%) of the voting securities of a
corporation or other business organization with voting securities or (ii) a fifty percent (50%) or greater interest in the net assets or profits of a partnership or other business organization without voting securities. The Parties acknowledge
that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case
such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management or policies of such entity. 

1.2 “COMBINATION PRODUCT” means a product, including a package of related products sold together as a kit, which contains
(i) a component that is a PRODUCT; and (ii) one or more biologically active functional components (“OTHER ACTIVE INGREDIENTS”) that are or which could be sold separately and which perform a useful function independent of the
PRODUCT component, such that the PRODUCT component can also function independently of the OTHER ACTIVE INGREDIENTS. OTHER ACTIVE INGREDIENTS specifically exclude, without limitation, the following: slide, plasticware (such as tubes and plates),
glassware, water and buffers. 
 1.3 “CORPORATE PARTNER” means any non-AFFILIATE, non-SUBLICENSEE entity which agrees to compensate, at a minimum including payment of RESEARCH SUPPORT PAYMENTS, COMPANY or an AFFILIATE or SUBLICENSEE for COMPANY’s or AFFILIATE’s or SUBLICENSEE’s
practice of the PATENT RIGHTS, LICENSED PRODUCTS and/or LICENSED PROCESSES on behalf or in collaboration with such entity, including without limitation for discovery and drug development activities for LICENSED PRODUCTS. 

1.4 “CORPORATE PARTNER INCOME” means any payments that COMPANY receives from a CORPORATE PARTNER in consideration of for the
performance of a LICENSED PROCESS by COMPANY, including without limitation upfront fees, milestone and bonus payments, but specifically excluding (i) royalties on NET SALES due under Section 4.1(d), (ii) RESEARCH SUPPORT PAYMENTS,
(iii) bona fide loans, (iv) payment of patent expenses incurred by COMPANY that CORPORATE PARTNER reimburses to COMPANY, and (v) equity investments in COMPANY by CORPORATE PARTNER at fair market value. 

  
 4 

 1.5 “FIELD” means therapeutics and treatments for all diseases in humans
other than (i) therapeutics and treatments utilizing [***] for infectious diseases, and (ii) therapeutics and treatments targeting [***] for cancer. 

1.6 “FUNDING THRESHOLD” shall mean the moment at which COMPANY or PARENT shall have received, since the date of
COMPANY’s incorporation, a total of [***] in cumulative funding from all sources of capital, including without limitation, debt, research grants from public and private sources, the proceeds from sales of the COMPANY’s or PARENT’s
equity securities, and committed proceed from sales of the COMPANY’s or PARENT’s equity securities, and committed proceed for equity and research funding in connection with a strategic alliance or corporate partnering transaction with
third parties. 
 1.7 “IDENTIFIED PRODUCT” means any product identified, selected or determined to have biological activity
or utility by the use of LICENSED PRODUCTS or LICENSED PROCESSES when the product itself or the manufacture or use of such product does not infringe the PATENT RIGHTS. 

1.8 “IND” shall mean, with respect to a particular LICENSED PRODUCT, an Investigational New Drug application submitted to the
FDA, or a corresponding application filed with any foreign counterpart regulatory agency, seeking approval to begin tests of a new drug in human subjects. 

1.9 “KNOW-HOW” shall mean know-how solely or
jointly owned by WHITEHEAD related to the inventions claimed in the PATENT RIGHTS and the use of such inventions, but specifically excluding KNOW-HOW relating to the WHITEHEAD/ARIZONA PATENT RIGHTS. 

1.10 “LICENSED PRODUCT” shall mean any product that, in whole or in part: 

(i) absent the license granted hereunder, would infringe one or more VALID CLAIMS of the PATENT RIGHTS in the country in which the product is
made, used or sold; or 
 (ii) is manufactured by using a LICENSED PROCESS or that, when used, practices a LICENSED PROCESS, in each case in
the country in which the LICENSED PROCESS is practiced. 
 1.11 “LICENSED PROCESS” shall mean any process that, absent the
license granted hereunder, would infringe one or more VALID CLAIMS of the PATENT RIGHTS or which uses a LICENSED PRODUCT as defined in Section 1.10(i) above. 

  
 5 

 1.12 “NDA” shall mean a New Drug Application submitted to the FDA seeking
approval to market and sell a LICENSED PRODUCT in the United States of America, or a corresponding application filed with any foreign counterpart regulatory agency seeking approval to market and sell a LICENSED PRODUCT in a country in the Territory.

 1.13 “NET SALES” means the gross amount received by COMPANY and its AFFILIATES and SUBLICENSEES for PRODUCTS sold to a
third party purchaser, less the following, in each case related specifically to the PRODUCT and actually allowed and taken by such third parties and not otherwise recovered by or reimbursed to COMPANY, its AFFILIATES or SUBLICENSEES: 

 

	 	(i)	 [***]; 

  

	 	(ii)	 [***]; 

  

	 	(iii)	 [***]; 

  

	 	(iv)	 [***]; and 

  

	 	(v)	 [***]. 

No deductions shall be made for [***]. For clarity, sales of PRODUCT between COMPANY and an AFFILIATE, or by COMPANY or an AFFILIATE to a
SUBLICENSEE (or vice versa), in each case for subsequent sale to a third party purchaser shall not be considered a sale until the subsequent sale is made to such third party purchaser. 

In the event that non-monetary consideration is received for PRODUCTS, NET SALES shall be calculated
based on the fair market value of such non-monetary consideration, including all elements of such consideration. 

COMBINATION PRODUCT: 
 In the event a PRODUCT is
sold in any country in the form of a COMBINATION PRODUCT, NET SALES, for the purposes of determining royalty payments for such COMBINATION PRODUCT under Section 4.1(d), shall mean the gross amount received for the COMBINATION PRODUCT less the
deductions set forth in clauses (i)- (vi) of this Section above, multiplied by a proration factor that is determined as follows: 
  

	 	1.13.1	 If the PRODUCT component and all OTHER ACTIVE INGREDIENTS in such COMBINATION PRODUCT were sold separately in
such country during the same or immediately preceding REPORTING PERIOD, the proration factor shall be determined by the formula [A/(A+B)] where: A is the average gross sale price in such country of the PRODUCT during such period when sold separately
from the OTHER ACTIVE INGREDIENTS, and B is the sum of the average gross sales prices in such country of the OTHER ACTIVE INGREDIENTS during such period when sold separately from the PRODUCT. 

  
 6 

	 	1.13.2	 If the PRODUCT is sold independently of the OTHER ACTIVE INGREDIENTS of the COMBINATION PRODUCT in such
country, but the OTHER ACTIVE INGREDIENTS in such COMBINATION PRODUCT were not separately sold in such country during the same or immediately preceding REPORTING PERIOD, the proration factor shall be determined by the formula [A/C] where: A is the
average gross sales price of the PRODUCT in such country during such period sold independently, and C is the average gross sales price in such country during such period of such COMBINATION PRODUCT. 

 

	 	1.13.3	 If the PRODUCT is not separately sold in such country but the OTHER ACTIVE INGREDIENTS contained in such
COMBINATION PRODUCT are separately sold in such country during the same or immediately preceding REPORTING PERIOD, the proration factor shall be determined by the formula [(D-E)/D] where: D is the average
gross sales price of such COMBINATION PRODUCT in such country during the REPORTING PERIOD and E is the sum of the average gross sales prices of the OTHER ACTIVE INGREDIENTS contained in such COMBINATION PRODUCT in such country during the same or
immediately preceding REPORTING PERIOD. 

  

	 	1.13.4	 If neither the PRODUCT nor the OTHER ACTIVE INGREDIENTS contained in the COMBINATION PRODUCT are separately
sold in such country during the same or immediately preceding REPORTING PERIOD, the proration factor shall be determined by WHITEHEAD and COMPANY in good faith negotiations, taking into account, without limitation, the relative value contributed by
each component. In the event that WHITEHEAD and COMPANY are unable to agree upon a proration factor within one hundred and twenty (120) days of first commercial sale to a third party purchaser of the COMBINATION PRODUCT, then COMPANY, at its
own expense, shall have the right to refer the determination of such proration factor to an independent third party expert mutually acceptable to the Parties, such acceptance not to be unreasonable withheld or delayed, within three (3) months.

  
 7 

 1.14 “PATENT CHALLENGE” means that COMPANY, its AFFILIATES or SUBLICENSEES,
anywhere in the TERRITORY, institutes or otherwise initiates (or in any way aids any third party in instituting or initiating), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or
its foreign counterparts, any claim, demand, action, or cause of action for declaratory relief, damages, or for an enjoinment, injunction, or any other equitable remedy, including any interference,
re-examination, review, opposition, or any similar proceeding, in each case, alleging that any claim in the PATENT RIGHTS is invalid, unenforceable, or otherwise not patentable or that the PATENT RIGHTS would
not be infringed by COMPANY’s, its AFFILIATE’s, its SUBLICENSEE’s or other third party’s activities absent the rights and licenses granted hereunder.  

1.15 “PATENT RIGHTS” means: 
  

	 	(i)	 the United States and international patents listed on Appendix A;

  

	 	(ii)	 the United States and international patent applications and/or provisional applications listed on
Appendix A and the resulting patents that issue directly therefrom; 

  

	 	(iii)	 claims of any patent applications claiming priority to any of the provisional applications listed on
Appendix A that are directed to subject matter specifically described in the patents and patent applications listed on Appendix A and any divisionals, continuations, claims of continuation-in-part applications, and continued prosecution applications (and their relevant international equivalents) of the patent applications listed on Appendix A and of such
patent applications that claim priority to any of the provisional applications listed on Appendix A, to the extent the claims are directed to and wholly supported by subject matter specifically described in the patent
applications listed on Appendix A, and those claims in the resulting patents that issue directly therefrom; and 

  

	 	(iv)	 claims of any patents resulting from reissues, reexaminations, or extensions (and their relevant international
equivalents) of the patents described in (i), (ii), and (iii) above that are directed to subject matter specifically described in the patents and patent applications listed on Appendix A. 

1.16 “PLATFORM DEVELOPMENT” shall mean research and development activities designed to improve and/or enhance COMPANY’s
target discovery and drug discover technology. 
 1.17 “PRODUCT” shall mean either a LICENSED PRODUCT or an IDENTIFIED
PRODUCT or both. 

  
 8 

 1.18 “RESEARCH SUPPORT PAYMENTS” means payments to COMPANY or an AFFILIATE
or SUBLICENSEE from a CORPORATE PARTNER or SUBLICENSEE for the purposes of funding the costs of bona fide research and development of PRODUCTS or LICENSED PROCESSES and that are expressly intended only to fund or pay for: (i) the purchase,
lease or use of equipment, supplies, products or services, (ii) the use of employees and/or consultants to achieve a research and/or development goal for PRODUCTS or LICENSED PROCESSES or (iii) reasonable, allocable overhead attributable
to the expenses described in (i) and (ii) and determined in accordance with United States generally accepted accounting principles, as indicated by those payments’ inclusion in a written agreement between COMPANY or an AFFILIATE and the
CORPORATE PARTNER or SUBLICENSEE. 
 1.19 “REPORTING PERIOD” shall begin on the first day of each calendar quarter and end
on the last day of such calendar quarter. 
 1.20 “SUBLICENSE INCOME” shall mean any payments that COMPANY receives from a
SUBLICENSEE in consideration of the sublicense of the rights granted COMPANY under Section 2.1, including without limitation license fees, milestone payments, license maintenance fees, and other payments, but specifically excluding
(i) royalties on NET SALES, (ii) RESEARCH SUPPORT PAYMENTS, (ii) payments made as consideration for debt or equity securities, (iv) amounts received in reimbursement for costs incurred by COMPANY or its AFFILIATES or SUBLICENSEES
(e.g. patent costs), and (v) amounts received for a grant of rights to any intellectual property and/or technology other than the PATENT RIGHTS. 

1.21 “SUBLICENSE” means: 

(i) any right granted, license given or agreement entered into by COMPANY to or with a third party, under or with respect to or permitting any
use of PATENT RIGHTS or otherwise granting rights to such third party under the rights granted COMPANY under Section 2.1; 
 (ii) any
option or other right granted by COMPANY to any other third party to negotiate for or receive any of the rights described under clause (i); or, 

(iii) any standstill or similar obligation undertaken by COMPANY toward a third party not to grant any of the rights described in clause
(i) or (ii) to such third party, in each case regardless of whether such grant of rights, license given or agreement entered into is referred to or is described as a SUBLICENSE. 

1.22 “SUBLICENSEE” shall mean any non-AFFILIATE third party granted a SUBLICENSE to
the rights granted COMPANY under Section 2.1. 

  
 9 

 1.23 “TANGIBLE PROPERTY” means the biological materials listed in Appendix
B, whether by themselves or incorporated into another material, and any progeny and unmodified derivatives thereof. Appendix B may be amended by mutual written agreement by the Parties. 

1.24 “TERM” shall mean the term of this Agreement, which shall commence on the EFFECTIVE DATE and shall remain in effect
until the expiration or abandonment of all issued patents and filed patent applications within the PATENT RIGHTS, unless earlier terminated in accordance with the provisions of this Agreement. 

1.25 “TERRITORY” shall mean worldwide. 

1.26 “VALID CLAIM” means a claim in (i)an issued and unexpired patent within the PATENT RIGHTS, which claim has not been
revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and which has not been admitted to be invalid or unenforceable
through reissue or disclaimer or otherwise; or (ii) a pending patent application under the PATENT RIGHTS which has not been abandoned or finally disallowed without possibility of appeal or re-filing of
such application and which has not been pending for more than seven (7) years from the date such application was first examined and has been prosecuted in good faith. The invalidity of a particular claim in one or more countries shall not
invalidate such claim in the remaining countries of the TERRITORY. 
 2. GRANT OF RIGHTS 

2.1 License Grants. Subject to the terms of this Agreement, WHITEHEAD hereby grants to COMPANY and its AFFILIATES for the TERM a
royalty-bearing license under the PATENT RIGHTS, the KNOW-HOW and the TANGIBLE PROPERTY to develop, commercialize, make, have made, use, sell, offer to sell, lease, and import PRODUCTS, and to use the KNOW-HOW and to use and make the TANGIBLE PROPERTY, in the FIELD in the TERRITORY and to develop and perform LICENSED PROCESSES in the FIELD in the TERRITORY. 

COMPANY acknowledges that there may be third party licenses required to be obtained by COMPANY for commercial use of the TANGIBLE PROPERTY.
The above grant of rights with respect to the TANGIBLE PROPERTY is expressly subject to this condition and it is the responsibility of COMPANY to obtain such third party licenses. WHITEHEAD has endeavored to identify to COMPANY all such third
parties from whom licenses are required, to its knowledge. 

  
 10 

 2.2 Exclusivity. The license granted above under the PATENT RIGHTS shall be
exclusive, except for WHITEHEAD Case no. [***], as to which the license is subject to a non-exclusive license previously granted to Merck Sharp & Dohme Corp.; provided, however, that with
respect to the WHITEHEAD/PFIZER PATENT RIGHTS, the exclusive license applies only to WHITEHEAD’s right, as a joint owner, to grant licenses under said PATENT RIGHTS under United States patent law. The license granted above to KNOW-HOW and TANGIBLE PROPERTY shall be non-exclusive. 
 2.3
Sublicenses. COMPANY shall have the right to grant sublicenses (through multiple tiers) of its rights under Section 2.1. COMPANY shall incorporate terms and conditions into its sublicense agreements sufficient to enable COMPANY to comply
with this Agreement. Each SUBLICENSEE must be subject to a written agreement that contains obligations, terms and conditions in favor of HHMI or the HHMI Indemnitees, as applicable, that are substantially similar to those undertaken by COMPANY in
favor of HHMI or the HHMI Indemnitees, as applicable, under this Agreement and intended for the protection of the HHMI Indemnitees, including, without limitation, the obligations, terms and conditions regarding indemnification, insurance and
HHMI’s third party beneficiary status. COMPANY shall also include provisions in all sublicenses to provide that in the event that SUBLICENSEE brings a PATENT CHALLENGE against WHITEHEAD or assists another party in bringing a PATENT CHALLENGE
against WHITEHEAD (except as required under a court order or subpoena) then COMPANY may end the PATENT CHALLENGE or terminate the sublicense as the COMPANY may choose. COMPANY shall promptly furnish WHITEHEAD with a fully signed photocopy of any
sublicense agreement with a SUBLICENSEE. Upon termination of this Agreement for any reason, any SUBLICENSEE not then in default shall be granted a license from WHITEHEAD under rights and terms equivalent to the sublicense rights and terms which
COMPANY previously granted to such SUBLICENSEE to the extent such rights and terms are not inconsistent with this Agreement. 
  

  
 11 

 2.4 U.S. Manufacturing. COMPANY agrees to comply with any obligations imposed on
WHITEHEAD and/or COMPANY by 35 U.S.C. §204 and/or other provisions of the Bayh-Dole Act as codified in 35 U.S.C. §§200-212, and implemented by 37 C.F.R 401 in connection with the manufacturing
of LICENSED PRODUCTS used or sold in the United States. WHITEHEAD agrees to cooperate with COMPANY in the filing of requests for the waiver of any obligations under 35 U.S.C. §204. 

2.5 Retained Rights. 

(a) WHITEHEAD, MIT, UM and others. WHITEHEAD, MIT, UM, UC, UW and ARIZONA retain the right to practice under the PATENT
RIGHTS for research, teaching, and educational purposes. In addition, UC retains a royalty-free, non-sublicensable right to practice the UC PATENT RIGHTS for any purpose outside the FIELD. 

(b) Academic and Not-For-Profit Research
Institutes. WHITEHEAD, MIT, UM, UC, UW and ARIZONA retain the right to grant licenses to academic and not-for-profit research institutes to practice under the PATENT
RIGHTS for research, teaching, and educational purposes. 
 (c) Federal Government. COMPANY acknowledges that the
U.S. federal government retains a royalty-free, non-exclusive, non-transferable license to practice any government-funded invention claimed in any PATENT RIGHTS as
set forth in 35 U.S.C. §§ 201-211, and the regulations promulgated thereunder, as amended, or any successor statutes or regulations. 

(d) HHMI. COMPANY acknowledges that it has been informed that certain PATENT RIGHTS,
KNOW-HOW and TANGIBLE PROPERTY were developed, at least in part, by employees of HHMI and that HHMI has a paid-up, non-exclusive,
irrevocable license to use certain of the PATENT RIGHTS, KNOW-HOW and TANGIBLE PROPERTY for HHMI’s research purposes, but with no right to assign or sublicense (the “HHMI License”). This
licenseis explicitly made subject to the HHMI License. 
 2.6 Future Improvements. WHITEHEAD will notify COMPANY at the earliest of
(a) publication of the Lindquist Lab Invention (as defined below), (b) publication of a patent application claiming the Lindquist Lab Invention, or (c) concurrently with marketing to third parties if and when WHITEHEAD seeks to license any
Lindquist Lab Invention. “Lindquist Lab Invention” shall mean any invention developed or conceived within three (3) 

  
 12 

 
years of the effective date of this Agreement from the WHITEHEAD laboratory of Susan Lindquist (including such invention dominated by any of the PATENT RIGHTS) or any related patent rights or
tangible property. Neither COMPANY, nor any other parties will be given priority not given to other parties in negotiating a license to any Lindquist Lab Invention, subject to any obligations arising from the funding of the research leading to such
inventions. 
 2.7 No Additional Rights. Nothing in this Agreement shall be construed to confer any rights upon COMPANY by
implication, estoppel, or otherwise as to any technology or patent rights of WHITEHEAD or any other entity other than under the PATENT RIGHTS, KNOW-HOW and TANGIBLE PROPERTY, regardless of whether such
technology or patent rights shall be dominant or subordinate to any PATENT RIGHTS, KNOW-HOW or TANGIBLE PROPERTY. 

2.8 Publication Rights. Nothing in this Agreement shall limit the rights of any of WHITEHEAD, MIT, UM, ARIZONA, UW, HHMI or UC to
publish research results in accordance with the respective general policies of the relevant institution. 
 2.9 Transfer of TANGIBLE
PROPERTY. WHITEHEAD will use reasonable efforts to effect, promptly following the Effective Date, the transfer to COMPANY of the TANGIBLE PROPERTY. To the extent there are any costs incurred in connection with such transfer, COMPANY shall
reimburse WHITEHEAD for such costs. 
 3. COMPANY DILIGENCE OBLIGATIONS 

3.1 Development Requirements. COMPANY shall use commercially reasonable efforts, or shall cause its AFFILIATES and SUBLICENSEES to use
commercially reasonable efforts, to develop LICENSED PRODUCTS or LICENSED PROCESSES and to introduce LICENSED PRODUCTS or LICENSED PROCESSES into the commercial market; thereafter, COMPANY or its AFFILIATES or SUBLICENSEES shall use commercially
reasonable efforts to make LICENSED PRODUCTS or LICENSED PROCESSES reasonably available to the public. Specifically, COMPANY or AFFILIATE or SUBLICENSEE shall fulfill the following obligations: 

  
 13 

	 	(i)	 Within [***] after the EFFECTIVE DATE, COMPANY shall furnish WHITEHEAD with a written research and development
plan describing the major tasks to be achieved in order to bring to market a LICENSED PRODUCT, specifying the number of staff and other resources to be devoted to such commercialization effort. 

 

	 	(ii)	 Within [***] after the end of each calendar year, COMPANY shall furnish WHITEHEAD with a written report
(consistent with Section 5.1(a)) on the progress of its efforts during the immediately preceding calendar year to develop and commercialize LICENSED PRODUCTS. The report shall also contain a discussion of intended efforts and sales projections
for the year in which the report is submitted. Each plan and report provided to WHITEHEAD under this Section shall be treated as confidential information of COMPANY and not disclosed or used by WHITEHEAD other than to confirm COMPANY’s
compliance with its obligations under this Agreement. 

 3.2 Diligence Requirements. Until the first regulatory
approval for a LICENSED PRODUCT, COMPANY or a SUBLICENSEE, alone or together, shall perform any one of the following with respect to PLATFORM DEVELOPMENT or a LICENSED PRODUCT, in a given calendar year: 

 

	 	(i)	 expend a minimum of [***]for PLATFORM DEVELOPMENT and/or development of a LICENSED PRODUCT or LICENSED PROCESS;

  

	 	(ii)	 [***]; 

  

	 	(iii)	 [***]; 

  

	 	(iv)	 [***]; 

  

	 	(v)	 [***]; 

  

	 	(vi)	 [***]; 

  

	 	(vii)	 [***]; 

  

	 	(viii)	 [***]. 

In the event that COMPANY or its SUBLICENSEES, alone or together, has not performed at least one of Sections 3.1(i) through
(ii) and 3.2(i) through (viii) during such calendar year with respect to PLATFORM DEVELOPMENT or a LICENSED PRODUCT or LICENSED PROCESS, then WHITEHEAD may treat such failure as a material breach in accordance with
Section 12.3(b). 

  
 14 

 4. ROYALTIES AND PAYMENT TERMS 

4.1 Consideration for Grant of Rights. 

(a) License Issue Fee and Patent Cost Reimbursement. COMPANY shall pay to WHITEHEAD, within [***] days of the EFFECTIVE
DATE, a license issue fee of [***] dollars (calculated as [***] minus [***], the amount of the Option Fee under the Option Agreement between the Parties, dated December 10, 2014), together with such amounts as are required as reimbursement in
accordance with Section 6.3 for expenses incurred as of the EFFECTIVE DATE in connection with obtaining the PATENT RIGHTS. These payments are nonrefundable and not creditable against running royalties or license maintenance fees. 

(b) License Maintenance Fees. COMPANY shall pay to WHITEHEAD the following license maintenance fees on January 1 of
each year set forth below: 
  

			
	 Year
	  	Maintenance Fee
	 2017
	  	$[***]
	 2018
	  	$[***]
	 2019
	  	$[***]
	 2020
	  	$[***]
	 2021 and every year thereafter
	  	$[***]

 This license maintenance fee is nonrefundable; however, the license maintenance fee may be
credited to running royalties subsequently due on NET SALES earned during the same calendar year, if any. License maintenance fees paid in excess of running royalties due in such calendar year shall not be creditable to amounts due for future years.

 (c) Milestone Payments. During the Term, COMPANY shall pay to WHITEHEAD the following milestone payments upon
achievement of the following milestones whether by COMPANY, its AFFILIATE or SUBLICENSEE. The following payments shall apply to [***]. 
  

	 	(i)	 [***] 

  

	 	(ii)	 [***] 

  
 15 

	 	(iii)	 [***] 

  

	 	(iv)	 [***] 

For subsequent LICENSED PRODUCTS beyond the first two for the first indication, COMPANY shall make payments at [***] of the above rates for each such LICENSED
PRODUCT. Following the first indication, COMPANY shall make payments (A) at[***] of the above rates for first two LICENSED PRODUCTS for each additional indication of such first two LICENSED PRODUCTS, and (B) at [***] of the above rates for
each subsequent LICENSED PRODUCT beyond the first two for each additional indication of such subsequent LICENSED PRODUCT. 

These milestone payments are nonrefundable and noncreditable. 

(d) Running Royalties. COMPANY shall pay to WHITEHEAD running royalties on: 

 

	 	(i)	 LICENSED PRODUCTS. NET SALES of LICENSED PRODUCTS by COMPANY, AFFILIATES and SUBLICENSEES (combined) as
follows: 

 cumulative NET SALES of $[***] 

cumulative NET SALES of $[***] 

cumulative NET SALES of [***] 

cumulative NET SALES of [***]; 
  

	 	(ii)	 IDENTIFIED PRODUCTS. NET SALES of IDENTIFIED PRODUCTS by COMPANY, AFFILIATES and SUBLICENSEES: [***].

 Running royalties shall be payable for each REPORTING PERIOD and shall be due to WHITEHEAD within [***]
days of the end of each REPORTING PERIOD 

  
 16 

 Running royalties for each LICENSED PRODUCT under this Section 4.1(d)
shall be due on a country-by-country basis for so long as the manufacture, use or sale of such LICENSED PRODUCT in such country infringes a VALID CLAIM of the PATENT
RIGHTS. 
 Running royalties for each IDENTIFIED PRODUCT under this Section 4.1(d) shall be due for a period extending
ten (10) years from the date of the first sale for consumption by an end user patient of each said IDENTIFIED PRODUCT on a country by country basis. The Parties expressly agree that such a payment period is not an extension of the PATENT RIGHTS
beyond their term, but rather is a period determined for the convenience of the Parties in recognition of the value of the PATENT RIGHTS in discovering IDENTIFIED PRODUCTS and as appropriate compensation for the rights granted herein.
Royalties on IDENTIFIED PRODUCTS shall be owed to WHITEHEAD at the royalty rate and for the duration set forth above in this Section 4.1(d) based on NET SALES of the IDENTIFIED PRODUCT whether such NET SALES are by COMPANY, AFFILIATES,
SUBLICENSEES or any other third party transferee or assignee. 
 (e) Sharing of SUBLICENSE INCOME and CORPORATE PARTNER
INCOME. COMPANY shall pay WHITEHEAD a share of all SUBLICENSE INCOME and all CORPORATE PARTNER INCOME received by COMPANY or AFFILIATES as follows: 

[***] of all such INCOME if licensed before the first dosing in a Phase II trial of the LICENSED PRODUCT or IDENTIFIED PRODUCT to which such
INCOME pertains; 
 [***] of all such INCOME if licensed after the first dosing in a Phase II trial of the LICENSED PRODUCT or IDENTIFIED
PRODUCT to which such INCOME pertains. 
 Such amounts shall be payable for each REPORTING PERIOD and shall be due to
WHITEHEAD within [***] days of the end of each REPORTING PERIOD. 
 (f) Consequences of a PATENT CHALLENGE. In the
event that (i) COMPANY or any of its AFFILIATES brings a PATENT CHALLENGE against WHITEHEAD, or (ii) COMPANY or any of its AFFILIATES assists another party in bringing a PATENT CHALLENGE against WHITEHEAD (except as required under a

  
 17 

 
court order or subpoena), and (iii) WHITEHEAD does not choose to exercise its rights to terminate this Agreement pursuant to Section 12.4, then: in the event that such a PATENT
CHALLENGE is successful, COMPANY will have no right to recoup any royalties paid during the period of challenge. In the event that a PATENT CHALLENGE is unsuccessful, COMPANY shall reimburse WHITEHEAD for all reasonable legal fees and expenses
incurred in their defense against the PATENT CHALLENGE. 
 (g) No Multiple Royalties. If the manufacture, use, lease,
or sale of any LICENSED PRODUCT or the performance of any LICENSED PROCESS is covered by more than one of the PATENT RIGHTS, multiple royalties shall not be due. 

(h) Royalty Stacking. If COMPANY is contractually required to pay royalties to any one or more third parties (other than
AFFILIATES) in order to practice the PATENT RIGHTS with respect to a particular LICENSED PRODUCT or LICENSED PROCESS, COMPANY shall be entitled to reduce running royalties payable to WHITEHEAD with respect to that LICENSED PRODUCT or LICENSED
PROCESS by [***] of the aggregate royalties payable by COMPANY to such third parties; provided, however, that in no event will the royalties due to WHITEHEAD for such LICENSED PRODUCT or LICENSED PROCESS be, after giving effect to such
reduction and all other offsets and credits allowed under this Agreement , less than [***] of the running royalties otherwise due. 

(i) Equity. 

(1) Initial Grant. PARENT, at the direction of the COMPANY, shall issue a total of 3,000 Common Units (as defined in the
Amended and Restated Operating Agreement dated as of August 14, 2015, the “PARENT LLC Agreement”) of PARENT (the “ License Units”) in the name of WHITEHEAD and of such persons as WHITEHEAD shall direct (“Whitehead
Holders”), and each Whitehead Holder shall receive such License Units as WHITEHEAD shall direct. Appendix C lists said License Units distribution. Such issuance shall be recorded on the books and records of PARENT. The License Units shall
not be Incentive Units. 

  
 18 

 COMPANY and PARENT represent to WHITEHEAD that, as of the EFFECTIVE DATE,
the aggregate number of License Units equals [***] of the PARENT’s issued and outstanding Units calculated on a “Fully Diluted Basis.” For purposes of this Section 4.1(i), “Fully Diluted Basis” shall mean that the total
number of issued and outstanding Units of the PARENT shall be calculated to include conversion of all issued and outstanding securities then convertible into Units (including any Convertible Promissory Notes convertible into Units sold to investors
but excluding the Bridge Units (as defined in the PARENT LLC Agreement)), the exercise of all then outstanding options and warrants to purchase Units (other than the Bridge Warrants (as defined in the PARENT LLC Agreement)), whether or not then
exercisable, and shall assume the issuance or grant of all securities reserved for issuance pursuant to any PARENT incentive equity plan in effect on the date of the calculation. 

(2) Anti-Dilution Protection. PARENT shall issue additional Common Units to WHITEHEAD and each Whitehead Holder pro
rata, such that WHITEHEAD’s and the Whitehead Holders’ ownership of outstanding Units shall not fall below [***] on a Fully Diluted Basis, as calculated after giving effect to the anti-dilutive issuance. Such issuances shall continue until
and including the moment at which PARENT achieves the FUNDING THRESHOLD (the “Funding Threshold Date”). Thereafter, no additional Units shall be due to any institution or any Whitehead Holder pursuant to this section. 

(3) Participation in Future Private Equity Offerings. After the Funding Threshold Date, WHITEHEAD (specifically not
including Whitehead Holders) shall have the right to purchase additional Units in any private offering by the PARENT of its equity securities in exchange for cash, to maintain its pro rata ownership as calculated immediately prior to such offering
on a Fully Diluted Basis, pursuant to the terms and conditions at least as favorable as those granted to the other offerees. PARENT may satisfy its obligations under this Section 4.1(i)(3) by offering WHITEHEAD the right to purchase additional
Units by delivering written notice to WHITEHEAD within [***] of the closing of any such private offering and WHITEHEAD shall then have [***] from the date such notice is delivered to exercise such right to purchase all or any portion of such Units
by 

  
 19 

 
delivery of written notice to PARENT. All rights granted pursuant to this Section 4.1(i)(3) shall terminate immediately prior to a firm commitment underwritten public offering of the
PARENT’s equity securities or upon a Sale of the Company (as defined in the PARENT LLC Agreement), whichever event occurs first. 
 4.2
Payments. 
 (a) Method of Payment. All payments under this Agreement should be made payable to “Whitehead
Institute for Biomedical Research” and sent to WHITEHEAD’s address identified in Section 14.1. Each payment should reference this Agreement and identify the obligation under this Agreement that the payment satisfies. 

(b) Payments in U.S. Dollars. All payments due under this Agreement shall be drawn on a United States bank and shall be
payable in United States dollars. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working day of the calendar quarter of
the applicable REPORTING PERIOD. Such payments shall be without deduction of exchange, collection, or other charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as permitted
in the definition of NET SALES. 
 (c) Late Payments. Any payments by COMPANY that are not paid on or before the date
such payments are due under this Agreement shall bear interest, to the extent permitted by law, at two percentage points above the Prime Rate of interest as reported in the Wall Street Journal on the date payment is due. 

5. REPORTS AND RECORD KEEPING 

5.1 Frequency of Reports. 

(a) Before First Commercial Sale. Prior to the first commercial sale to an end user purchaser of any LICENSED PRODUCT or
first commercial performance of any LICENSED PROCESS, COMPANY shall deliver reports to WHITEHEAD annually, within [***] days of the end of each calendar year, containing information concerning the immediately preceding calendar year, as further
described in Section 5.2. 

  
 20 

 (b) Upon First Commercial Sale of a LICENSED PRODUCT or Commercial
Performance of a LICENSED PROCESS. COMPANY shall report to WHITEHEAD the date of first commercial sale to an end user purchaser of a LICENSED PRODUCT and the date of first commercial performance of a LICENSED PROCESS within [***] days of
occurrence in each country. 
 (c) After First Commercial Sale. After the first commercial sale of a LICENSED PRODUCT
to an end user purchaser or first commercial performance of a LICENSED PROCESS, COMPANY shall deliver reports to WHITEHEAD within sixty (60) days of the end of each REPORTING PERIOD, containing information concerning the immediately preceding
REPORTING PERIOD, as further described in Section 5.2. 
 5.2 Content of Reports and Payments. Each report delivered by COMPANY to
WHITEHEAD shall contain at least the following information for the immediately preceding REPORTING PERIOD or calendar year, as applicable: 
  

	 	(i)	 the number of LICENSED PRODUCTS sold, leased or distributed by COMPANY, its AFFILIATES and SUBLICENSEES to end
user purchasers in each country, and, if applicable, the number of LICENSED PRODUCTS used by COMPANY, its AFFILIATES and SUBLICENSEES in the provision of services in each country; 

 

	 	(ii)	 the PATENT RIGHTS that cover each such LICENSED PRODUCT sold, leased or distributed by COMPANY, its AFFILIATES
and SUBLICENSEES; 

  

	 	(iii)	 the gross price charged by COMPANY, its AFFILIATES and SUBLICENSEES for each LICENSED PRODUCT and, if
applicable, the gross price charged for each LICENSED PRODUCT used to provide services in each country; 

  

	 	(iv)	 calculation of NET SALES for the applicable REPORTING PERIOD in each country, including a listing of applicable
deductions; 

  
 21 

	 	(v)	 total royalty payable on NET SALES in U.S. dollars, together with the exchange rates used for conversion;

  

	 	(vi)	 the amount of SUBLICENSE INCOME received by COMPANY from each SUBLICENSEE and the amount deliverable to
WHITEHEAD from such SUBLICENSE INCOME, including an itemized breakdown of the sources of income comprising the SUBLICENSE INCOME; and 

  

	 	(vii)	 the number of sublicenses entered into for the PATENT RIGHTS, LICENSED PRODUCTS and/or LICENSED PROCESSES.

 If no amounts are due for any REPORTING PERIOD, the report shall so state. Each report provided to WHITEHEAD under this
Section 5 shall be treated as confidential information of COMPANY and not disclosed or used by WHITEHEAD other than to confirm COMPANY’s compliance with its reporting obligations under this Section 5, to exercise its rights under this
Agreement, and to provide such report to employees of HHMI and trustees who have a need to know such information. 
 5.3 Financial
Statements. On or before the [***] day following the close of COMPANY’s fiscal year, COMPANY shall provide WHITEHEAD with COMPANY’s financial statements for the preceding fiscal year including, at a minimum, a balance sheet and an
income statement, certified by COMPANY’s treasurer or chief financial officer or by an independent auditor. 
 5.4 Record
keeping. COMPANY shall maintain, and shall cause its AFFILIATES and SUBLICENSEES to maintain, complete and accurate records relating to the rights and obligations under this Agreement and any amounts payable to WHITEHEAD in relation to this
Agreement, which records shall contain sufficient information to permit WHITEHEAD to confirm the accuracy of any reports delivered to WHITEHEAD and compliance in other respects with this Agreement. The relevant party shall retain such records for at
least three (3) years following the end of the calendar year to which they pertain, during which time WHITEHEAD or WHITEHEAD’s appointed agents, shall have the right, at WHITEHEAD’s expense, to inspect such records during normal
business hours to verify any reports and payments made or compliance in other respects under this Agreement. In the event that any audit performed under this Section reveals an underpayment in excess [***] for any twelve (12) month period,

  
 22 

 
COMPANY shall bear the full cost of such audit and shall remit any amounts due to WHITEHEAD within [***] days of receiving notice thereof from WHITEHEAD. WHITEHEAD may exercise its audit rights
under this Section 5.4 no more frequently than once in any calendar year. All records, documents and other information disclosed to or accessed by WHITEHEAD under this Section 5.4 shall be the confidential information of COMPANY and not
disclosed or used by WHITEHEAD other than to exercise its rights under this Agreement, and to provide such records, documents and other information to employees of HHMI and trustees who have a need to know such information. 

6. PATENT PROSECUTION 

6.1 Responsibility for PATENT RIGHTS. WHITEHEAD shall prepare, file, prosecute, and maintain all of the PATENT RIGHTS. COMPANY shall
have reasonable advance opportunities to advise WHITEHEAD and shall cooperate with WHITEHEAD in such filing, prosecution and maintenance. WHITEHEAD will consult with COMPANY on the prosecution of the PATENT RIGHTS and COMPANY’s suggestions and
requests regarding patent prosecution will be reasonably considered and included unless WHITEHEAD reasonably concludes in good faith that they are not beneficial to the PATENT RIGHTS. WHITEHEAD shall keep COMPANY timely informed with regard to the
provisional application, patent application and maintenance processes. WHITEHEAD shall deliver to COMPANY copies of all provisional applications, patent applications, amendments, related correspondence, and other related matters in a timely manner,
both for United States and international (non-United States) filings. Notwithstanding anything herein to the contrary, on a
country-by-country basis, if COMPANY notifies WHITEHEAD in writing of COMPANY’s objection to any such filing, prosecution or maintenance with respect to any
provisional application(s) or patent application(s) within the scope of PATENT RIGHTS, such provisional application(s) and patent application(s) shall thereafter not qualify as PATENT RIGHTS hereunder with respect to the particular country in
question, and COMPANY shall not be responsible for patents costs or expenses of such provisional application(s) and patent application(s) incurred thereafter. 

6.2 International (non-United States) Filings. Appendix D is a list of
countries in which patent applications corresponding to the United States patent applications and provisional applications listed in Appendix A shall be filed, prosecuted, and maintained.
Appendix D may be amended by mutual agreement of COMPANY and WHITEHEAD. 

  
 23 

 6.3 Payment of Expenses. Payment of all reasonable out-of-pocket fees and costs, including attorneys’ fees, relating to the filing, prosecution and maintenance of the PATENT RIGHTS shall be the responsibility of COMPANY, whether such amounts were
incurred before or after the EFFECTIVE DATE but not after the Term. As of October 15, 2015, WHITEHEAD, UC and UW have incurred $[***] for such patent-related fees and costs. (Such amount includes fees and costs invoiced prior to
October 15, 2015. Additional fees and costs may be invoiced after such date, which will be for COMPANY’s account.) WHITEHEAD shall invoice COMPANY for $[***] of such costs upon execution of this Agreement, and for $[***] on the first
anniversary of execution of this Agreement. COMPANY shall reimburse all amounts due pursuant to this Section 6.3 within [***] days of invoicing; late payments shall accrue interest pursuant to Section 4.2(c). In the event that WHITEHEAD
licenses the PATENT RIGHTS in a field separate from the FIELD to a third party, where possible, a reasonable adjustment to COMPANY’s patent reimbursement payment shall be made to account for such third party license. In all instances, WHITEHEAD
shall pay the fees prescribed for large entities to the United States Patent and Trademark Office. 
 7. INFRINGEMENT 

7.1 Notification of Infringement. Each Party agrees to provide written notice to the other Party promptly after becoming aware of any
infringement of the PATENT RIGHTS. 
 7.2 Right to Prosecute Infringements. 

(a) COMPANY Right to Prosecute. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD in
the TERRITORY, COMPANY, to the extent permitted by law, shall have the right, under its own control and at its own expense, to prosecute any third party infringement of the PATENT RIGHTS in the FIELD in the TERRITORY, subject to Sections 7.4
and 7.5. If required by law, WHITEHEAD shall permit any action under this Section to be brought in its name, including being joined as a party-plaintiff, provided that COMPANY shall reimburse WHITEHEAD for any reasonable out-of-pocket costs WHITEHEAD incurs in connection with such action. 

  
 24 

 Prior to commencing any such action, COMPANY shall consult with WHITEHEAD
and shall consider the views of WHITEHEAD regarding the advisability of the proposed action and its effect on the public interest. COMPANY shall not enter into any settlement, consent judgment, or other voluntary final disposition of any
infringement action under this Section which imposes obligations on WHITEHEAD or MIT beyond those set forth herein, or which invalidates or restricts the PATENT RIGHTS, without the prior written consent of WHITEHEAD (subject to concurrence of MIT,
as applicable), which consent shall not be unreasonably withheld or delayed. 
 (b) WHITEHEAD Right to Prosecute. In
the event that COMPANY is unsuccessful in persuading the alleged infringer to desist or fails to have initiated an infringement action within a reasonable time after COMPANY first becomes aware of the basis for such action, WHITEHEAD shall have the
right, at its sole discretion, to prosecute such infringement under its sole control and at its sole expense, and any recovery obtained shall belong to WHITEHEAD. 

7.3 Declaratory Judgment Actions. In the event that a PATENT CHALLENGE is brought against WHITEHEAD or COMPANY by a third party
(including without limitation oppositions, reissues, interferences, reexaminations and other litigation-like proceedings), COMPANY, at its option, shall have the right within [***] days after commencement of such action to take over the sole defense
of the action at its own expense subject to Sections 7.4 and 7.5. If COMPANY does not exercise this right, WHITEHEAD may take over the sole defense of the action at WHITEHEAD’s sole expense, subject to Sections 7.4 and 7.5. In
the event such a PATENT CHALLENGE results in the filing of an infringement counterclaim, then any recovery obtained from such a counterclaim shall be distributed in accordance with Section 7.5. 

7.4 Offsets. COMPANY may offset a total of [***] of any expenses incurred (whether by COMPANY or by WHITEHEAD reimbursed by COMPANY
pursuant to Section 7.2(a)) under Sections 7.2 or 7.3 against any payments due to WHITEHEAD under Article 4, provided that in no event shall such payments under Article 4, when aggregated with any other offsets and
credits allowed under this Agreement, be reduced by more than [***] in any REPORTING PERIOD. If such [***] of COMPANY’s expenses and costs exceeds the amount of payments deducted by COMPANY for any REPORTING PERIOD, then COMPANY may to that
extent reduce the payments due to WHITEHEAD in succeeding REPORTING PERIODS, but never by more than [***] of the total payments due in any one calendar year with respect to the patent(s) and patent application(s) subject to such suit. 

  
 25 

 7.5 Recovery. Any recovery obtained in an action brought by the COMPANY under
Sections 7.2 or 7.3 shall be distributed as follows: 
  

	 	(i)	 each Party shall be reimbursed for any expenses incurred in the action (including the amount of any royalty or
other payments withheld from WHITEHEAD as described in Section 7.4); 

  

	 	(ii)	 COMPANY shall receive an amount equal to its lost profits on the infringing sales if awarded, and COMPANY shall
pay to WHITEHEAD based upon such amount a reasonable approximation of the royalties under Article 4 based on hypothetical NET SALES that COMPANY would have paid to WHITEHEAD if COMPANY had sold the infringing products, processes and services rather
than the infringer; 

  

	 	(iii)	 if COMPANY shall receive damages based on a reasonable royalty, such reasonable royalty on the infringing sales
will be divided as [***] to COMPANY and the remainder to WHITEHEAD; and 

  

	 	(iv)	 as to special or punitive damages, the Parties shall share equally in any award. 

7.6 Cooperation. Each Party agrees to cooperate in any action under this Article which is controlled by any other Party, provided that
the controlling Party reimburses the cooperating Parties promptly for any costs and expenses incurred by the cooperating Parties in connection with providing such assistance. 

7.7 Right to Sublicense. So long as COMPANY remains the exclusive licensee of the PATENT RIGHTS in the FIELD in the TERRITORY, COMPANY
shall have the sole right to sublicense any alleged infringer in the FIELD in the TERRITORY for future use of the PATENT RIGHTS in accordance with the terms and conditions of this Agreement relating to sublicenses. Any upfront fees as part of such
sublicense shall be treated as set forth in Article 4. 

  
 26 

 8. INDEMNIFICATION AND INSURANCE 

8.1 Indemnification. 

(a) Indemnity. COMPANY shall indemnify, defend, and hold harmless WHITEHEAD, UM, MIT, ARIZONA, UW and UC, and the
trustees (including the Curators of UM, the Arizona Board of Regents, the University of Washington Board of Regents and the members of the MIT Corporation), officers, faculty, students, employees, and agents of each of them, and their respective
successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss, or expense (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) incurred by or imposed upon any of the
Indemnitees in connection with any third party claims, suits, actions or demands arising out of or based upon the exercise of any rights granted to COMPANY under this Agreement or any breach of this Agreement by COMPANY. COMPANY’S
indemnification under this Section 8.1(a) does not apply to any Losses to the extent that they are attributable to the grossly negligent or willful activities of any of the Indemnitees, or to the intentional wrongdoing or intentional misconduct
of any of the Indemnitees. 
 (b) Indemnification of HHMI. HHMI, and its trustees, officers, employees, and agents
(collectively, “HHMI Indemnitees”), will be indemnified, defended by counsel acceptable to HHMI, and held harmless by COMPANY from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or
nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “Claims”), based upon, arising out of, or otherwise relating to this Agreement or any sublicense, or the use,
handling, storage, or disposition of the TANGIBLE PROPERTY by COMPANY or others who possess the TANGIBLE PROPERTY through a chain of possession leading back, directly or indirectly, to COMPANY, including without limitation any cause of action
relating to product liability.. The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI Indemnitee.
Notwithstanding any other provision of this Agreement, COMPANY’s obligations to defend, indemnify and hold harmless the HHMI Indemnitees under this paragraph will not be subject to any limitation or exclusion of liability or damages or
otherwise limited in any way. 

  
 27 

 (c) Procedures. The Indemnitees agree to provide COMPANY with prompt
written notice of any claim, suit, action, or demand for which indemnification is sought under Section 8.1(a) of this Agreement. COMPANY agrees, at its own expense, to provide attorneys reasonably acceptable to Indemnitees to defend against any
such claim. The Indemnitees shall cooperate fully with COMPANY in such defense and will permit COMPANY to conduct and control such defense and the disposition of such claim, suit, or action (including all decisions relative to litigation, appeal,
and settlement); provided, however, that any Indemnitee shall have the right to retain its own counsel, at the expense of COMPANY, if representation of such Indemnitee by the counsel retained by COMPANY would be inappropriate because of actual or
potential differences in the interests of such Indemnitee and any other party represented by such counsel. COMPANY agrees to keep WHITEHEAD reasonably informed of the progress in the defense and disposition of such claim and to consult reasonably
with WHITEHEAD with regard to any proposed settlement. 
 8.2 Insurance. COMPANY shall obtain and carry in full force and effect
commercial general liability insurance and, beginning at the time any PRODUCT is being commercially manufactured, distributed or sold by, or any LICENSED PROCESS is being performed commercially by, COMPANY or by an AFFILIATE or SUBLICENSEE, product
liability and errors and omissions insurance. Such insurance: 
  

	 	(i)	 shall be issued by an insurer licensed to practice in the Commonwealth of Massachusetts or an insurer pre-approved by WHITEHEAD, such approval not to be unreasonably withheld; 

  

	 	(ii)	 shall list WHITEHEAD, MIT, UM, UC, UW, HHMI and ARIZONA as additional insureds thereunder; and

  

	 	(iii)	 shall require [***] days written notice to be given to WHITEHEAD prior to any cancellation or material change
thereof. 

 In addition, the COMPANY shall obtain and carry in full force and effect general liability insurance,
including products liability insurance, and errors and omissions insurance for the conduct of all clinical trials involving human subjects by no later than the commencement thereof. Such insurance shall comply with subsections (ii) and (iii)
above. 

  
 28 

 All product liability insurance policies shall be occurrence-based policies. All errors and
omissions liability policies shall have endorsements to cover bodily injury and damage to tangible property and shall have “retroactive dates” of the earliest to occur of the events described in subclauses (i) and (ii) of the last
paragraph of this Section 8.2 and shall continue for the time durations specified in such last paragraph. 
 The limits of such
insurance shall not be less than [***] per occurrence with an aggregate of [***] bodily injury including death; and [***] per occurrence with an aggregate of [***] for property damage. In the alternative, COMPANY may self-insure subject to prior
approval of WHITEHEAD, MIT, UM, ARIZONA, UW and UC. COMPANY shall provide WHITEHEAD with Certificates of Insurance evidencing compliance with this Section. COMPANY shall continue to maintain such insurance or self-insurance after the expiration or
termination of this Agreement during any period in which COMPANY or any AFFILIATE or SUBLICENSEE continues (i) to commercially manufacture, distribute or sell a product that was a PRODUCT under this Agreement or (ii) to perform
commercially a service that was a LICENSED PROCESS under this Agreement, and, in both cases, thereafter for a period of ten (10) years. 

9. REPRESENTATIONS OR WARRANTIES 

WHITEHEAD hereby represents and warrants that (a) it has the power and authority to grant the licenses provided for herein to COMPANY,
and that it has not earlier granted, or assumed any obligation to grant, any rights in the PATENT RIGHTS to any third party that would conflict with the rights granted to COMPANY herein; and (b) this Agreement constitutes the legal, valid and
binding obligation of WHITEHEAD, enforceable against WHITEHEAD in accordance with its terms. 
 EXCEPT AS MAY OTHERWISE BE EXPRESSLY SET
FORTH IN THIS AGREEMENT, WHITEHEAD, UM, MIT, ARIZONA, UW AND UC MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE PATENT RIGHTS, TANGIBLE PROPERTY OR KNOW-HOW, EXPRESS OR IMPLIED, INCLUDING
WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A 

  
 29 

 
PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. Specifically, and not to
limit the foregoing, WHITEHEAD, UM, MIT, ARIZONA, UW and UC make no warranty or representation, except as expressly set forth in this Agreement, (i) regarding the validity or scope of the PATENT RIGHTS, and (ii) that the exploitation of
the PATENT RIGHTS, TANGIBLE PROPERTY or any LICENSED PRODUCT or LICENSED PROCESS will not infringe any patents or other intellectual property rights of WHITEHEAD, UM, MIT, ARIZONA, UC, UW or of a third party. 

IN NO EVENT SHALL COMPANY, OR WHITEHEAD, UM, MIT, ARIZONA, UW OR UC, OR THE TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES OF ANY OF
THEM, BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGES OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER COMPANY, WHITEHEAD, UM, MIT, ARIZONA OR UC SHALL BE ADVISED, SHALL HAVE OTHER REASON TO
KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. 
 The TANGIBLE PROPERTY is experimental in nature and will be used with
prudence and appropriate caution, since not all of its characteristics are known. 
 10. ASSIGNMENT 

This Agreement is personal to COMPANY and no rights or obligations may be assigned by COMPANY without the prior written consent of WHITEHEAD.
The foregoing notwithstanding, COMPANY may assign its rights and obligations under this Agreement (a) to an Affiliate, and (b) to a successor in connection with the merger, consolidation, or sale of all or substantially all of its assets
or that portion of its business to which this Agreement relates; provided, however, that such assignee shall agree in writing to be bound by the terms and conditions of this Agreement as if the Affiliate or successor, as applicable, were
COMPANY under this Agreement on or before the effective date of the assignment. 

  
 30 

 11. GENERAL COMPLIANCE WITH LAWS 

11.1 Compliance with Laws. COMPANY shall use reasonable commercial efforts to comply with all commercially material local, state,
federal, and international laws and regulations relating to the development, manufacture, use, and sale of LICENSED PRODUCTS and LICENSED PROCESSES. 

11.2 Export Control. COMPANY and its AFFILIATES and SUBLICENSEES shall comply with all United States laws and regulations controlling
the export of certain commodities and technical data, including without limitation all Export Administration Regulations of the United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for
the export of certain types of commodities and technical data to specified countries. COMPANY hereby gives written assurance that it will comply with, and will cause its AFFILIATES and SUBLICENSEES to comply with, all United States export control
laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its AFFILIATES or SUBLICENSEES, and that it will indemnify, defend, and hold WHITEHEAD, MIT and HHMI harmless (in accordance with
Section 8.1) for the consequences of any such violation. 
 11.3 Non-Use of Name. COMPANY
and its AFFILIATES and SUBLICENSEES shall not use the name of “Whitehead Institute”, “Massachusetts Institute of Technology”, “University of Chicago”, “University of Missouri”, “Lincoln Laboratory”,
“University of Washington”, “The Arizona Board of Regents”, “University of Arizona”, “Howard Hughes Medical Institute”, or any variation, adaptation, or abbreviation thereof, or of any of their trustees,
officers, faculty, students, employees (including, except as permitted under the consulting agreement between Dr. Lindquist and Yumanity signed December 1, 2014, Dr. Lindquist), or agents, or any trademark owned by WHITEHEAD, HHMI,
UM, MIT, ARIZONA, UW or UC, or any terms of this Agreement (the “Protected Names”), in any promotional material or other public announcement without the prior written consent of the relevant party, which consent such party may withhold in
its sole discretion. The foregoing notwithstanding, without the consent of WHITEHEAD and such other foregoing institutions, (i) COMPANY may make factual statements during the term of this Agreement that COMPANY has a license from
“Whitehead Institute” under one or more of the patents, provisional applications and/or patent applications comprising the PATENT RIGHTS, but may not use any other Protected Names, and (ii) COMPANY may comply with disclosure
requirements of all applicable laws relating to its business, including, without limitation, United States, state and foreign securities laws. 

  
 31 

 11.4 Marking of LICENSED PRODUCTS. To the extent commercially feasible, required by
applicable law and consistent with prevailing business practices, COMPANY shall mark, and shall cause its AFFILIATES and SUBLICENSEES to mark, all LICENSED PRODUCTS that are manufactured or sold under this Agreement with the number of each issued
patent under the PATENT RIGHTS that applies to such LICENSED PRODUCT. 
 12. TERMINATION 

12.1 Voluntary Termination by COMPANY. COMPANY shall have the right to terminate this Agreement, for any reason, (i) upon at least
[***] prior written notice to WHITEHEAD, such notice to state the date at least [***] in the future upon which termination is to be effective, and (ii) upon payment of all amounts due to WHITEHEAD through such termination effective date. 

12.2 Cessation of Business. If COMPANY ceases to carry on its business related to this Agreement, WHITEHEAD shall have the right to
terminate this Agreement immediately upon written notice to COMPANY. 
 12.3 Termination for Default. 

(a) Nonpayment. In the event COMPANY fails to pay any amounts due and payable to WHITEHEAD hereunder, and fails to make
such payments within [***] after receiving written notice of such failure, WHITEHEAD may terminate this Agreement immediately upon written notice to COMPANY. 

(b) Material Breach. In the event COMPANY commits a material breach of its obligations under this Agreement, except for
breach as described in Section 12.3(a), and fails to cure that breach within [***] days after receiving written notice thereof, WHITEHEAD may terminate this Agreement immediately upon written notice to COMPANY, subject to the completion of the
dispute resolution procedure set forth in Article 13 and any subsequent cure period. 

  
 32 

 12.4 Termination as a Consequence of Patent Challenge. 

(a) By COMPANY. If COMPANY or any of its AFFILATES brings a PATENT CHALLENGE against WHITEHEAD or assists others in
bringing a PATENT CHALLENGE against WHITEHEAD (except as required under a court order or subpoena), then WHITEHEAD may immediately terminate this Agreement and/or the license granted hereunder. 

(b) By SUBLICENSEE. If a SUBLICENSEE brings a PATENT CHALLENGE or assists another party in bringing a PATENT CHALLENGE
(except as required under a court order or subpoena), then WHITEHEAD may send a written demand to COMPANY to end the PATENT CHALLENGE or terminate such sublicense as the COMPANY may choose. If COMPANY fails to have the SUBLICENSEE terminate the
PATENT CHALLENGE or to so terminate such sublicense within sixty (60) days after WHITEHEAD’s demand, WHITEHEAD may immediately terminate this Agreement and the licenses granted hereunder. 

12.5 Effect of Termination. 

(a) Survival. The following provisions shall survive the expiration or termination of this Agreement: Articles 1,
8, 9, 10, 13 and 14, and Sections 2.3 (last sentence), 4.1(h), 5.2 (obligation to provide final report and payment), 5.4, 11.1, 11.2 and 12.5. 

(b) Inventory. Upon the early termination of this Agreement, COMPANY and its AFFILIATES and SUBLICENSEES may complete
and sell any work-in-progress and inventory of PRODUCTS that exist as of the effective date of termination, provided that: 

 

	 	(i)	 COMPANY pays WHITEHEAD the applicable running royalty or other amounts due on such sales of PRODUCTS in
accordance with the terms and conditions of this Agreement; and 

  

	 	(ii)	 COMPANY and its AFFILIATES and SUBLICENSEES shall complete and sell all work-in-progress and inventory of PRODUCTS within [***] months after the effective date of termination. 

  
 33 

 (c) Pre-termination
Obligations. In no event shall termination of this Agreement release COMPANY, AFFILIATES, or SUBLICENSEES from the obligation to pay any amounts that became due on or before the effective date of termination. 

(d) Sublicenses. Upon termination, SUBLICENSEES in good standing shall continue by way of a direct license with
WHITEHEAD in accordance with Section 2.3. 
 13. DISPUTE RESOLUTION 

13.1 Mandatory Procedures. The Parties agree that any dispute arising out of or relating to this Agreement shall be resolved solely by
means of the procedures set forth in this Article, and that such procedures constitute legally binding obligations that are an essential provision of this Agreement. If any Party fails to observe the procedures of this Article, as may be modified by
their written agreement, the other Parties may bring an action for specific performance of these procedures in any court of competent jurisdiction. 

13.2 Equitable Remedies. Although the procedures specified in this Article are the sole and exclusive procedures for the resolution of
disputes arising out of or relating to this Agreement, any Party may seek a preliminary injunction or other provisional equitable relief if, in its reasonable judgment, such action is necessary to avoid irreparable harm to itself or to preserve its
rights under this Agreement. 
 13.3 Dispute Resolution Procedures. 

(a) Mediation. In the event any dispute arising out of or relating to this Agreement remains unresolved within [***]
days from the date the affected Party informed the other Parties of such dispute, any Party may initiate mediation upon written notice to the other Party (“Notice Date”), whereupon all Parties shall be obligated to engage in a mediation
proceeding under the then current Center for Public Resources (“CPR”) Model Procedure for Mediation of Business Disputes (http://www.cpradr.org), except that specific provisions of this Article shall override inconsistent provisions of the
CPR Model Procedure. The mediator will be selected from the CPR Panels of Neutrals. If the Parties cannot agree upon the selection of a mediator within [***] days after the Notice Date, then upon the request of any Party, the CPR shall appoint the
mediator. The Parties shall attempt to resolve the dispute through mediation until the first of the following occurs: 

  
 34 

	 	(i)	 the Parties reach a written settlement; 

 

	 	(ii)	 the mediator notifies the Parties in writing that they have reached an impasse; 

 

	 	(iii)	 the Parties agree in writing that they have reached an impasse; or 

 

	 	(iv)	 the Parties have not reached a settlement within ninety (90) days after the Notice Date.

 (b) Trial Without Jury. If the Parties fail to resolve the dispute through mediation, or if no
Party elects to initiate mediation, each Party shall have the right to pursue any other remedies legally available to resolve the dispute, provided, however, that the Parties expressly waive any right to a jury trial in any legal proceeding under
this Article. 
 13.4 Performance to Continue. Each Party shall continue to perform its undisputed obligations under this Agreement
pending final resolution of any dispute arising out of or relating to this Agreement; provided, however, that a Party may suspend performance of its undisputed obligations during any period in which any other Party fails or refuses to perform its
undisputed obligations. Nothing in this Article is intended to relieve COMPANY from its obligation to make undisputed payments pursuant to Articles 4 and 6 of this Agreement. 

13.5 Statute of Limitations. The Parties agree that all applicable statutes of limitation and time-based defenses (such as estoppel and
laches) shall be tolled while the procedures set forth in Section 13.3(a) are pending. The Parties shall cooperate in taking any actions necessary to achieve this result. 

13.6 HHMI. Notwithstanding the foregoing, no dispute affecting the rights or property of HHMI shall be subject to the dispute resolution
provisions set forth in this Section 13 above. 
 14. MISCELLANEOUS 

14.1 Notice. Any notices required or permitted under this Agreement shall be in writing, shall specifically refer to this Agreement,
and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, or registered or certified mail, postage prepaid, return receipt requested, to the following addresses or facsimile numbers of the Parties: 

  
 35 

 If to WHITEHEAD: 

Whitehead Institute for Biomedical Research 

Nine Cambridge Center 
 Cambridge,
MA 02142 
 Attention: Intellectual Property Office 

Tel: 617-258-5104 

Fax: 617-258-6294 

If to COMPANY: 
 Yumanity
Therapeutics, Inc. 
 Address: 790 Memorial Drive, Suite 2C 

                Cambridge, MA 02139 

Attention: Chief Business Officer 

Tel: 617-409-5300 

Fax: 617-409-5252 

All notices under this Agreement shall be deemed effective upon receipt. A Party may change its contact information immediately upon written
notice to the other Parties in the manner provided in this Section. 
 14.2 Governing Law. This Agreement and all disputes arising out
of or related to this Agreement, or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of
Massachusetts, U.S.A., without regard to conflict of laws principles, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. The state and
federal courts having jurisdiction over Cambridge, MA, USA, provide the exclusive forum for any PATENT CHALLENGE and/or any court action between the Parties relating to this Agreement. COMPANY submits to the jurisdiction of such courts and waives
any claim that such court lacks jurisdiction over COMPANY or its AFFILIATES or constitutes an inconvenient or improper forum. 
 14.3
Force Majeure. No Party will be responsible for delays resulting from causes beyond the reasonable control of such Party, including without limitation fire, explosion, flood, war, strike, or riot, or action, inaction or delay by any
governmental authority, provided that the nonperforming Party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are
removed. 
  

  
 36 

 14.4 Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise
modified only by means of a written instrument signed by all Parties. Any waiver of any rights or failure to act in a specific instance shall relate only to such instance and shall not be construed as an agreement to waive any rights or fail to act
in any other instance, whether or not similar. 
 14.5 Severability. In the event that any provision of this Agreement shall be held
invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any other provision of this Agreement, and the Parties shall negotiate in good faith to modify the Agreement to preserve (to the extent possible) their
original intent. If the Parties fail to reach a modified agreement within [***] days after the relevant provision is held invalid or unenforceable, then the dispute shall be resolved in accordance with the procedures set forth in Article 13.
While the dispute is pending resolution, this Agreement shall be construed as if such provision were deleted by agreement of the Parties. 

14.6 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective permitted
successors and assigns. 
 14.7 Headings. All headings are for convenience only and shall not affect the meaning of any provision of
this Agreement. 
 14.8 HHMI Third Party Beneficiary. HHMI is not a party to this Agreement and has no liability to any licensee,
sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name. 

14.9 Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to its subject matter and
supersedes all prior agreements or understandings between the Parties relating to its subject matter. 

  
 37 

 14.10 Interpretation. Whenever any provision of this Agreement uses the term
“including” (or “includes”), such term shall be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,” “hereby,” “hereunder,”
“hereof” and other equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. The term “or” means “and/or” hereunder. All
definitions set forth herein shall be deemed applicable whether the words defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Appendices in this Agreement are to Sections and Appendices of
this Agreement. References to any Sections include Sections and subsections that are part of the related Section (e.g., a section numbered “Section 3.2” would be part of “Section 3”, and references to
“Section 3.2” would also refer to material contained in the subsection described as “Section 3.2(a)”). Unless otherwise stated, dollar amounts set forth in this Agreement are U.S. dollars. 

14.11 Counterparts. This Agreement may be executed in counterparts with the same force and effect as if each of the signatories had executed
the same instrument. 

  
 38 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
duly authorized representatives. 
  

									
	For WHITEHEAD	 		 	For COMPANY:
					
	By:	 	 /s/ Carla DeMaria
	 		 	By:	 	 /s/ Paulash Mohsen

					
	Name:	 	Carla DeMaria	 		 	Name:	 	Paulash Mohsen
					
	Title:	 	Director of IP & Sponsored Programs	 		 	Title:	 	Chief Business Officer
					
	Date:	 	2/4/2016	 		 	Date:	 	Feb. 3, 2016

 SOLELY FOR THE PURPOSE OF SECTION 4.1(i), FOR PARENT: 

 

			
	By:	 	 /s/ Paulash Mohsen

	Name:	 	Paulash Mohsen
	Title:	 	Chief Business Officer
	Date:	 	Feb. 3, 2016

  
 39 

 APPENDIX A 

List of Patent Applications and Patents 

[***] 

  
 40 

 APPENDIX B 

Tangible Property 
 [***] 

  
 41 

 APPENDIX C 

Initial Unit Distribution to WHITEHEAD and Whitehead Holders 

[***] 

  
 42 

 APPENDIX D 

List of Countries (excluding United States) for which 

PATENT RIGHTS Applications Will Be Filed, Prosecuted and Maintained 

[***] 

  
 43 

 CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[***]”, HAS BEEN
EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

THIRD AMENDMENT 
 This
THIRD AMENDMENT, effective as of July 18, 2018 (the “AMENDMENT EFFECTIVE DATE”), amends the Tangible Property and Exclusive Patent License Agreement Dated February 4, 2016 (“LICENSE AGREEMENT”), by and between the
Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Yumanity Therapeutics, Inc. (“COMPANY”), a Delaware
corporation, and solely for the purpose of Section 4.1 (i) of the LICENSE AGREEMENT, Yumanity Holdings LLC (“PARENT”), a Delaware limited liability company, both with a principal office at 790 Memorial Drive, Suite 2C,
Cambridge, MA 02139 (together the “Parties”) 
 RECITALS 

WHEREAS, WHITEHEAD and COMPANY wish to modify the provisions of the LICENSE AGREEMENT, amended on August 8 2016 (the “FIRST
AMENDMENT”) and on April 13, 2016 (the SECOND AMENDMENT”); 
 WHEREAS, WHITEHEAD and The Massachusetts Institute of
Technology (“M.I.T.”) own certain THIRD AMENDMENT PATENT RIGHTS (as later defined in this Third Amendment) relating to WHITEHEAD Case No. [***]. The THIRD AMENDMENT PATENT RIGHTS were co-developed by
Dr. Susan Lindquist as a Howard Hughes Medical Institute (“HHMI”) employee at her laboratory at WHITEHEAD. 
 WHEREAS, M.I.T.
has entered into a Joint Invention Administration Agreement, effective July 13, 2017, that authorized WHITEHEAD to act as its sole and exclusive agent for the purposes of licensing the THIRD AMENDMENT PATENT RIGHTS and has authorized WHITEHEAD
to enter into this THIRD AMENDMENT on its behalf; 
 WHEREAS, WHITEHEAD desires to have the THIRD AMENDMENT PATENT RIGHTS developed and
commercialized to benefit the public by granting a license; and, 
 WHEREAS, COMPANY desires to obtain a
non-exclusive commercial license to the THIRD AMENDMENT PATENT RIGHTS and to add such THIRD AMENDMENT PATENT RIGHTS to the license grant under the LICENSE AGREEMENT. 

 NOW, THEREFORE, WHITEHEAD and COMPANY hereby agree as follows: 

Capitalized terms used herein and not defined herein shall have the respective meanings ascribed to such terms in the LICENSE AGREEMENT. 

1. (a) The following (hereinafter the “THIRD AMENDMENT PATENT RIGHTS”) are hereby included in the definition of PATENT RIGHTS in
Section 1.15 (which Section 1.15 is hereby amended) and will be added to Appendix A of the LICENSE AGREEMENT: 

[***]. 
 (b) Appendix A of the
LICENSE AGREEMENT is deleted in its entirety and replaced with Appendix A of this THIRD AMENDMENT, attached hereto. 
 2.
Section 2.2 of the LICENSE AGREEMENT is deleted in its entirety and replaced with the following: 
 “2.2 Exclusivity.
The license granted above under the PATENT RIGHTS shall be exclusive, except for WHITEHEAD Case No. [***] for which the license shall be non-exclusive, and, provided, however, that with respect to the WHITEHEAD/PFIZER PATENT RIGHTS, the exclusive
license applies only to WHITEHEAD’S right, as a joint owner, to grant licenses under said PATENT RIGHTS under United States patent law. The license granted above to KNOW-HOW and TANGIBLE PROPERTY shall be
non-exclusive.” 
 3. COMPANY shall be responsible for
one-half (1/2) of all reasonable out-of-pocket fees and costs, including attorneys’ fees, relating to the filing, prosecution and maintenance of the THIRD AMENDMENT
PATENT RIGHTS prior to the AMENDMENT EFFECTIVE DATE. As of the AMENDMENT EFFECTIVE DATE, such patent-related fees and costs total $[***] of which $[***] has been paid by COMPANY as of the AMENDMENT EFFECTIVE DATE. WHITEHEAD shall invoice COMPANY for
$[***] upon execution of this THIRD AMENDMENT for COMPANY to pay such amount to WHITEHEAD within [***] days of its receipt of such invoice. For the avoidance of doubt, per Section 6.3 of the LICENSE AGREEMENT, payment of all such costs incurred
after the AMENDMENT EFFECTIVE DATE shall be the responsibility of COMPANY as more specifically set forth in such Section 6.3. 

 4. As consideration for this THIRD AMENDMENT, COMPANY shall pay WHITEHEAD a case addition
fee of [***] within [***] days of the AMENDMENT EFFECTIVE DATE. This payment is nonrefundable. 
 5. The LICENSE AGREEMENT, as amended
hereby, in addition to the other amendments, is hereby ratified and confirmed in all respects and shall continue in full force and effect. The LICENSE AGREEMENT will, together with the FIRST AMENDMENT, SECOND AMENDMENT and this THIRD AMENDMENT, be
read and construed as a single instrument. All other terms and conditions of the LICENSE AGREEMENT are confirmed and remain in full force and effect. This THIRD AMENDMENT shall be binding upon, and shall inure to the benefit of, the parties hereto
and their respective successors and assigns. 
 IN WITNESS WHERE OF, the Parties have caused this THIRD AMENDMENT to be executed by their
duly authorized representatives. 
  

									
	For WHITEHEAD:	 	    	  	For COMPANY:
					
	By:	 	 /s/ Carla DeMaria
	 		  	By:	  	 /s/ Kenneth J. Rhodes

	Name:	 	Carla DeMaria	 		  	Name:	  	Kenneth J. Rhodes, Ph.D.
	Title:	 	Director of IP & Sponsored Programs	 		  	Title:	  	CSO
	Date:	 	July 25, 2018	 		  	Date:	  	July 18, 2018

 For PARENT: 
  

			
	By:	 	 /s/ Paulash Mohsen

	Name:	 	Paulash Mohsen
	Title:	 	CBO
	Date:	 	July 18, 2018

 APPENDIX A 

List of Patent Applications and Patents 

[***] 

 CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[***]”, HAS BEEN
EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

SECOND AMENDMENT 
 This
Second Amendment, effective as of April 13, 2016 (the “Effective Date”), amends the Exclusive Patent License Agreement Dated February 4, 2016 (“LICENSE AGREEMENT”), by and between the Whitehead Institute for
Biomedical Research (“WHITEHEAD”), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Yumanity Therapeutics, Inc. (“COMPANY”), a Delaware corporation, and solely for the
purpose of Section 4.1 (i) of the LICENSE AGREEMENT, Yumanity Holdings LLC (“PARENT”), a Delaware limited liability company, both with a principal office at 790 Memorial Drive, Suite 2C, Cambridge, MA 02139 (together the
“Parties”) 
 RECITALS 

WHEREAS, WHITEHEAD and the University of Arizona (“ARIZONA”) are the owners of certain WHITEHEAD/ARIZONA PATENT RIGHTS (as defined
in the LICENSE AGREEMENT) relating to WHITEHEAD Case No. [***]. The WHITEHEAD/ARIZONA PATENT RIGHTS were co-developed by Dr. Susan Lindquist as a Howard Hughes Medical Institute (“HHMI”)
employee at her laboratory at WHITEHEAD; 
 WHEREAS, COMPANY no longer wishes to support the WHITEHEAD/ARIZONA PATENT RIGHTS; 

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the Parties hereto agree to modify the LICENSE
AGREEMENT as follows: 
  

	 	1.	 The WHITEHEAD/ARIZONA PATENT RIGHTS shall be removed from the LICENSE AGREEMENT. 

 

	 	2.	 COMPANY will be responsible for all reasonable
out-of-pocket fees and costs, including attorneys’ fees, relating to the filing, prosecution and maintenance of the WHITEHEAD/ARIZONA PATENT RIGHTS incurred before
the Effective Date of this Second Amendment (including such costs incurred before the effective date of the LICENSE AGREEMENT). 

	 	3.	 The remaining terms and conditions of the LICENSE AGREEMENT shall remain intact. 

IN WITNESS WHERE OF, the Parties have caused this Second Amendment to be executed by their duly authorized representatives. 

 

									
	For WHITEHEAD:	 	    	  	For COMPANY:
					
	By:	 	 /s/ Carla DeMaria
	 		  	By:	  	 /s/ Kenneth J. Rhodes

	Name:	 	Carla DeMaria	 		  	Name:	  	Kenneth J. Rhodes, Ph.D.
	Title:	 	Director of IP & Sponsored Programs	 		  	Title:	  	Chief Scientific Officer
	Date:	 	June 6, 2016	 		  	Date:	  	June 6, 2016

 For PARENT: 
  

			
	By:	 	 /s/ Kenneth J. Rhodes

	Name:	 	Kenneth J. Rhodes, Ph.D.
	Title:	 	Chief Scientific Officer
	Date:	 	June 6, 2016

 CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[***]”, HAS BEEN
EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 

FIRST AMENDMENT 
 This
First Amendment, effective as of August 8,2016 (the “Effective Date”), amends the Tangible Property and Exclusive Patent License Agreement dated February 4, 2016 (“LICENSE AGREEMENT”), by and between the Whitehead
Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Yumanity Therapeutics, Inc. (“COMPANY”), a Delaware corporation, and
solely for the purpose of Section 4.1(i) of the LICENSE AGREEMENT, Yumanity Holdings, LLC (“PARENT”), a Delaware limited liability company, both with a principal office at 790 Memorial Drive, Suite 2C, Cambridge, MA 02139
(together the “Parties”). 
 RECITALS 

WHEREAS, WHITEHEAD is the owner of certain WHITEHEAD PATENT RIGHTS (as defined in the LICENSE AGREEMENT) relating to WHITEHEAD Case No. [***]
(the “AMYLOID PATENT RIGHTS”). The AMYLOID PATENT RIGHTS were co-developed by Dr. Susan Lindquist as a Howard Hughes Medical Institute (“HHMI”) employee at her laboratory at WHITEHEAD;

 WHEREAS, WHITEHEAD has identified that another WHITEHEAD employee, Sebastian Treusch has contributed to the AMYLOID PATENT RIGHTS and is
now an inventor of the AMYLOID PATENT RIGHTS (the “ADDED INVENTOR”); 
 WHEREAS, the ADDED INVENTOR has assigned his ownership
rights to the AMYLOID PATENT RIGHTS to WHITEHEAD; 
 WHEREAS, the ADDED INVENTOR shall be listed as a Whitehead Holder and shall receive a
number of shares previously allocated to WHITEHEAD in an amount equivalent to other inventors of the AMYLOID PATENT RIGHTS; 
 AND WHEREAS,
WHITEHEAD has also agreed to hold the share of equity allocated to the University of Washington on behalf of the University of Washington; 

 NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the
Parties hereto agree to modify the LICENSE AGREEMENT as follows: 
  

	 	1.	 APPENDIX C shall be deleted in its entirety and replaced with the following: 

APPENDIX C 
 [***] 

 

	 	2.	 The remaining terms and conditions of the LICENSE AGREEMENT shall remain intact. 

IN WITNESS WHEREOF, the Parties have caused this First Amendment to be executed by their duly authorized representatives. 

{signatures on following page} 

									
	For WHITEHEAD:	 	    	  	For COMPANY:
					
	By:	 	 /s/ Carla DeMaria
	 		  	By:	  	 /s/ Paulash Mohsen

	Name:	 	Carla DeMaria	 		  	Name:	  	Paulash Mohsen
	Title:	 	Director of IP & Sponsored Programs	 		  	Title:	  	Chief Business Officer
	Date:	 	August 8, 2016	 		  	Date:	  	August 9, 2016

 For PARENT: 
  

			
	By:	 	 /s/ Paulash Mohsen

	Name:	 	Paulash Mohsen
	Title:	 	Chief Business Officer

 Date:     August 9, 2016EX-10.18

 Exhibit 10.18 

License Agreement 
 This
License Agreement, made and entered into as of February 5, 2020 (“Agreement”), is by and between Yumanity Therapeutics, Inc., a Delaware corporation, registered to do business in Massachusetts, and having a place of
business located at 790 Memorial Drive, #2C, Cambridge, MA 02139 (“Licensee”) and MIL 40G, LLC a Delaware limited liability company having a place of business located at 40 Guest Street, Brighton, MA 02135
(“Licensor”). 
 RECITALS 

WHEREAS, Licensor, or its affiliate, has leased certain space located at 40 Guest Street, Brighton, MA 02135 (the
“Building”) through a lease agreement (the “Lease”) between Licensor and Courtside Realty, LLC (“Landlord”); and 

WHEREAS, Licensee desires to use certain space and services, as set forth below, for research and development, laboratory research and office
use. 
 For good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, the
parties agree as follows: 
  

	1.	 License. 

  

	 	(a)	 License Description. Licensor grants to Licensee the following (A) and (B), of which shall
constitute the Licensee’s license (the “License”), solely to, (i) use as office and laboratory space consistent with current zoning for the Building and all applicable laws; (ii) conduct Licensee’s business; and
(iii) collaborate with Licensor’s staff and other licensees in accordance with this Agreement: (A) a non-transferable, non-assignable license to
use Lab Suites F, G and H more specifically identified in the shaded portion of the floor plan attached to this Agreement as Exhibit 1 (“Lab Suites”), and (ii) use Office Suites F and G, more specifically
identified in the shaded portion of the floor plan attached to this Agreement as Exhibit 1 (“Office Suites”)(Lab Suites and Office Suites are collectively the “Licensed Premises”) and (B) a non-transferable, non-exclusive, non- assignable license to use any common areas (“Shared Premises”), subject to Licensor’s reasonable rules and
restrictions. Licensor shall deliver the Licensed Premises turnkeyed, at Licensor’s expense, per a mutually agreed upon delivery condition and inclusive of all elements of the attached Licensee space program and based on building standard
materials. Licensor shall deliver the Licensed Premises fully furnished with cabling and wiring included. Licensee shall have access to the furniture in the Licensed Premises for the entire Term at no additional cost; provided, however, that
Licensor shall not be required to provide any furniture above and beyond what is explicitly set forth herein. Licensor shall deliver the Licensed Premises with all systems exclusively servicing the Licensed Premises in good working condition and
suitable for laboratory uses. Licensor will deliver the Licensed Premises with code compliant demising walls and common area corridors, all as described in plans and specifications to be attached to this License as Exhibit 4. Licensee reserves the
right to perform an independent due diligence of Building’s base building infrastructure, provided Licensor is present and provided such due diligence is agreed upon by the Landlord and in accordance with the Lease. Subject to the delivery
requirements set forth in this License, Licensee shall accept the Licensed Premises and Shared Premises in their “as-is” conditions. Licensor shall maintain HVAC, electrical, life safety and plumbing
systems specifically servicing the Licensed Premises throughout the Term. Licensor shall remain responsible for all of the obligations of Licensor, as tenant, pursuant 

  
 1 

	 	
to the terms of the Lease and shall take commercially reasonable efforts to cause the Landlord to perform its obligations pursuant to the Lease. Licensor shall have no obligation to alter, repair
or otherwise prepare the Licensed Premises for Licensee’s use or to pay for, or provide any, improvements to the Licensed Premises except as expressly provided herein. Licensee shall not use the Licensed Premises or Shared Premises for any use
other than the foregoing, including but not limited to medical care or human clinical trials, without first obtaining written permission from Licensor, which Licensor may withhold in its sole discretion. 

 

	 	(b)	 Scope of License. The License shall not include access to any additional office or laboratory space in
the Building. Licensor retains all of the rights and privileges as the property owner that are not inconsistent with the provisions of this Agreement. Licensee understands and agrees that other licensee(s) may jointly occupy portions of the
Building, not including the Licensed Premises, which shall be exclusive to the Licensee, but including but not limited to the Shared Premises. Licensee agrees that, other than the Licensed Premises, use of any other portion of the Building shall not
be exclusive to Licensee. Sections 10, 11 and 13 below shall apply to any and all Claims (as defined below) arising out of, or in connection with, any other licensee(s), persons or entities using or occupying the Building. 

 

	 	(c)	 Occupants. The License shall only grant Licensee, and no more than 88 (eighty-eight) of Licensee’s
members, employees or agents (collectively, “Occupants”), access to the Licensed Premises and Shared Premises. 

  

	 	(d)	 Right of First Offer. The Licensee shall have a one-time Right
of First Offer (“ROFO”) on all fourth (4th) floor suites. Such ROFO shall only apply, however, after (i) such suite(s) has/have been licensed to a third party and
(ii) such third-party license has lapsed or been terminated. 

  

	2.	 Term and Termination. 

 

	 	(a)	 Term. Unless terminated earlier in accordance with this Section 2, the term
(“Term”) of this Agreement shall commence on April 1, 2020 (“Term Commencement Date”) and expire on March 31,2023 (“Expiration Date”). Under no circumstance shall Licensor be liable to
Licensee for failure to provide access to the Licensed Premises or Shared Premises on or before April 1, 2020; provided, however, that if Licensor is unable to provide Licensee access to the Licensed Premises, including but not limited to
Biosafety Level 1 and 2 permits, on April 1,2020, then the Term Commencement Date, Expiration Date, and Initial License Fee Commencement Date shall be extended by the number of days Licensor is unable to provide access to the
Licensed Premises, and the License Fee Commencement Date shall be extended by one and one-half day for each day that Licensor is unable to provide access to the Licensed Premises. Licensee shall have the
option to extend the Term of the License Agreement for total of three (3), one (1) year periods (“Extension Term”), provided that Licensee gives Licensor nine (9) months advance written notice prior to the
applicable Expiration Date. The License Fee during each Extension Term shall be set at fair market value, which shall be determined in accordance with industry standards and shall be comparable to
similar-sized spaces within the Boston market. 

  

  
 2 

	 	(b)	 Termination. Licensor may terminate this Agreement immediately for “cause” by giving written
notice to Licensee specifying the cause. “Cause” shall include, but is not limited to: (i) Licensee’s violation of this Agreement or any provisions contained in the Lease; (ii) Licensee’s failure to comply with any
covenants contained herein; or (iii) Licensee’s use of the Licensed Premises or Shared Premises in violation of any applicable laws or rules and procedures promulgated by Licensor or Landlord. Excepting instances in which the cause
threatens the health or safety of the Building or its occupants (in which no advance notice is required) as determined in good faith, or the cause arises out of Licensee’s failure to pay any sums hereunder (in which case Licensee shall be
permitted to cure such failure within five (5) days of notice from Licensor to Licensee), Licensee shall be in default hereunder if Licensee does not cure any cause set forth above within fifteen (15) days of written notice from Licensor
to Licensee. Upon the occurrence of any of the foregoing, and at any time thereafter, with or without notice or demand and without limiting Licensor in the exercise of any right or remedy that Licensor may have, Licensor may do any or all of the
following by written notice to Licensee or by any lawful means, (A) terminate Licensee’s access to the Licensed Premises, or (B) terminate the License. In either instance, Licensee shall immediately surrender the Licensed Premises to
Licensor. In such event, Licensor shall have the immediate right to re-enter and remove all persons and property from the Licensed Premises and Shared Premises, and such property may be removed and stored in a
public warehouse or elsewhere at the cost and for the account of Licensee, without being deemed guilty of trespass or becoming liable for any loss or damage that may be occasioned thereby. In the event that Licensor shall elect to so terminate this
License, then Licensor shall be entitled to recover from Licensee all direct and indirect damages incurred by Licensor by reason of Licensee’s default including, but not limited to, recovery of any broker’s fee paid by Licensor in relation
to this Agreement and all reasonable attorneys’ fees. Upon termination of this Agreement, the License shall expire and Licensee shall immediately vacate the Licensed Premises and Shared Premises. Under no circumstances shall Licensee, Licensor
or Landlord be liable for any alleged, purported, consequential or indirect damages resulting from Licensor or Landlord terminating this Agreement; provided, however, that Licensee may be liable for consequential or indirect damages arising out of
its (x) failure to comply with, or violation of, Section 8 below or (y) failure to timely vacate the Licensed Premises in accordance with this Section if and only if Licensee’s possession continues for thirty (30) days after
written notice from Licensor, which notice shall state that Licensee shall be liable for consequential and indirect damages if Licensee remains in possession of the Licensed Premises after such thirty (30) day period. 

 

	3.	 License Fee. 

  

	 	(a)	 Base Fee. Licensee shall pay a monthly license fee equal to $167,282.50 for the first four
(4) months of the Term (“Initial License Fee”), which Licensee shall pay in advance on or before the first day of each and every month during the Term by electronic payment to Licensor and shall commence on April 1,2020
(the “Initial License Fee Commencement Date”). Thereafter, Licensee shall pay a monthly license fee equal to $334,565.00 per month for the remainder of the first year of the Term (“License Fee”) which Licensee shall
pay in advance on or before the first day of each and every month during the Term by electronic payment to Licensor commencing on August 1, 2020 (the “License Fee Commencement Date”). The License Fee shall be subject to a three
percent (3%) increase upon each anniversary of the Term Commencement Date. 

  

	 	(b)	 Late Fee. If any payment of the Initial License Fee and/or License Fee, or any other payment due under
this Agreement, is not received by Licensor on or before the first day of each month, or when otherwise due, and is not received by Licensor for a period of five (5) days after written notice thereof from Licensor to Licensee, Licensee shall
pay to 

  
 3 

	 	
Licensor a late payment charge equal to five percent (5%) of the amount of such delinquent payment, in addition to any outstanding License Fee or any other payment due under this Agreement then
owing. Thereafter, Licensee shall pay eighteen percent (18%) interest on any outstanding License Fee or other payment due under this Agreement that remains unpaid; such interest shall accrue beginning the date such payment is due until the date such
payment is actually paid. 

  

	 	(c)	 Additional Fees. Licensee shall have the right to forty-two (42) non-revocable parking spaces adjacent to the Building at the prevailing monthly parking rate for the Building, which is subject to change. The current monthly parking for the Building is One Hundred and
Eighty Dollars ($180) per month. Additional parking may be available and is subject to Licensor’s discretion. 

  

	 	(d)	 Security Deposit. Licensee shall be required to pay a Security Deposit equal to $354,940.01
(“Security Deposit”). The purpose of the Security Deposit is to guarantee the full, prompt and faithful performance by Licensee of all of the terms, conditions, covenants, agreements, warranties and provisions of this Agreement to be
performed, fulfilled or observed by Licensee hereunder, including but not limited to the payment of the License Fee and other charges. If Licensee breaches any term or condition of this Agreement, said Security Deposit or any part thereof may be
used to pay any such payment or perform any obligations of the Licensee, and the Licensee shall immediately replace the amount of the Security Deposit so used. Said Security Deposit may be co-mingled with the
Licensor’s other funds, need not be kept in a separate account, and Licensor shall not be required to pay interest on same. Licensor shall promptly return the balance of the Security Deposit at the end of Term, as extended from time to time.
Licensor, from time to time, may transfer the Security Deposit to any mortgagee or any grantee or grantees to be held by such mortgagee, grantee or grantees as the Security Deposit hereunder on the above terms, and upon such transfer to such
mortgagee, grantee or grantees, Licensor thereupon shall be relieved from all further liability to the Licensee with respect to the Security Deposit, and Licensee thereafter shall look only to such mortgagee, grantee or grantees for the return of
the Security Deposit. 

  

	 	(e)	 Initial Payment. Licensee shall pay, immediately upon executing this Agreement, an amount equal to a
portion of the last month’s license fee ($347,359.35), and the Security Deposit ($354,940.01), and the Parking Fees (as defined below) associated with Licensee’s Parking Spaces (as defined below). As such, Licensee shall pay a total of
$702,299.36, plus the aforementioned Parking Fees, on or before the execution of this Agreement. 

  

	4.	 Service Agreement. Licensor agrees to provide to Licensee, during the entire Term of this Agreement, the
services set forth in the Service Agreement attached hereto as Exhibit 2. The License Fee shall cover and include the cost of the services set forth in the Service Agreement and, unless the scope of services requested by Licensee exceed those
set forth in the Service Agreement, Licensee shall not be assessed any additional fees for services contained in the Service Agreement. The Service Agreement shall be governed by the terms of this Agreement and if there is any conflict between the
covenants and representations contained in this Agreement and the Service Agreement, the terms of this Agreement shall prevail and be binding upon Licensor and Licensee. Licensor shall not be liable for any failure to provide the services set forth
in the Service Agreement to the extent such failure is beyond Licensor’s reasonable control. 

  
 4 

	5.	 Common Areas. Licensee hereby acknowledges that other licensees and/or occupants are occupying or may in
the future occupy other portions of the Building. Licensee’s use of the Licensed Premises, and access to and use of the common areas and any other services in connection with the Licensed Premises or this Agreement, shall be subject to any and
all rules and procedures reasonably promulgated by Licensor and/or Landlord and delivered to Licensee from time to time. Licensee’s compliance with such rules and procedures constitutes a material inducement to Licensor’s willingness to
enter into this Agreement; any violation thereof shall constitute a material breach of this Agreement. 

  

	6.	 Parking. During the Term, Licensee shall have a non-exclusive,
irrevocable license to use 42 (forty-two) unreserved parking spaces adjacent to the Building at the current monthly parking rate (“Licensee’s Parking Spaces”). Licensee shall have no
right to elect to reduce its number of Licensee’s Parking Spaces and shall be responsible for the Parking Fees (defined below) for such spaces regardless of whether its Occupants use Licensee’s Parking Spaces. Licensee shall pay, in
addition to the License Fee, monthly parking fees equal to the prevailing rates for the Building (“Parking Fees”) and shall pay such Parking Fees to Licensor at the time each License Fee payment is due. Additional parking may be
available and is subject to Licensor’s discretion. Parking rate is subject to change. 

  

	7.	 Modifications to Licensed Premises. Licensee shall not make any modification to the HVAC, structural,
telecommunications, electrical, life safety or plumbing systems of the Licensed Premises without Licensor’s prior written approval, which approval may be withheld or conditioned in Licensor’s sole discretion. For modifications outside of
the scope of the foregoing sentence, Licensee shall not make such modifications to the Licensed Premises without Licensor’s prior written approval, which approval may be not be unreasonably withheld, conditioned, or delayed. Licensee shall bear
the cost of any approved modifications to the Licensed Premises. All articles of personal property, and all business and trade fixtures, machinery and equipment, cabinet work, furniture and movable partitions, if any, paid for or installed by
Licensee in the Licensed Premises will be and remain the property of Licensee and may be removed by Licensee at any time, provided that Licensee, at its expense, shall repair any damage to the Licensed Premises caused by such removal or by the
original installation. Licensee shall remove all of Licensee’s personal property at the expiration of the Term of this Agreement or sooner termination of this Agreement, in which event the removal shall be done at Licensee’s expense and
Licensee, prior to the end of the Term of this Agreement or upon sooner termination of this Agreement, shall repair any damage to the Licensed Premises caused by its removal. 

 

	8.	 Hazardous Materials. Licensee shall also have the right to store in the Licensed Premises up to its pro
rata share of the quantity of Hazardous Materials allowed in the control zone within which the Licensed Premises are located, subject to local, state and federal law. Licensee shall strictly comply with all Environmental Laws, and all provisions set
forth in the Lease, to the extent such provisions relate to the Licensed Premises during the Term of this Agreement. For purposes hereof, “Environmental Laws” shall mean all laws, statutes, ordinances, rules and regulations of any
local, state or federal governmental authority having jurisdiction concerning environmental, health and safety matters, including but not limited to any discharge by Licensee or Licensee’s Occupants into the air, surface water, sewers, soil or
groundwater of any Hazardous Material (defined below) whether within or outside the Licensed Premises, including, without limitation (i) the Federal Water Pollution Control Act, 33 U.S.C. Section 1251 et seq., (ii) the Federal Resource
Conservation and Recovery Act, 42 U.S.C. Section 6901 et seq., (iii) the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Section 9601 et seq., (iv) the Toxic Substances Control Act of 1976,15 U.S.C.
Section 2601 et seq., and (v) Chapter 2 IE of the General Laws of Massachusetts. Licensee, at its sole cost and expense, shall comply with (a) Environmental Laws. Licensee, at its sole cost and expense, shall
comply with (a) Environmental Laws, and (b) any rules, requirements and safety procedures of the Massachusetts Department of Environmental Protection, 

  
 5 

	 	
the city in which the Building is located, and any insurer of the Building or the Licensed Premises with respect to Licensee’s use, storage and disposal of any Hazardous Materials.
Notwithstanding anything in this Agreement to the contrary, Licensee shall have no liability to Licensor or responsibility under this Agreement for any Hazardous Materials in, on, under or about the Licensed Premises that were not released,
discharged, stored or introduced by Licensee or its agents. Licensee understands and agrees that Licensor must decontaminate the Licensed Premise prior to Licensee vacating same and therefore Licensee shall fully cooperate with Licensor in the
aforementioned decontamination, which may include Licensee ceasing its operations and/or removing personal property prior to the expiration of the Term. The term “Hazardous Material” means asbestos, oil or any hazardous,
radioactive or toxic substance, material, waste or petroleum derivative which is or becomes regulated by any Environmental Law or which is designated as a “hazardous substance,” “hazardous material,” “oil,”
“hazardous waste” or toxic substance under any Environmental Law. Licensee shall follow all of Licensor’s Environmental Health and Safety (“EH&S”) guidelines and requirements that have been provided to Licensee,
which may be modified from time to time by Licensor provided that such modifications do not materially change Licensee’s rights hereunder. 

  

	9.	 Fire, Other Casualty; Eminent Domain. In the event of a fire or other casualty affecting the Building or
the Licensed Premises, or of a taking of all or a part of the Building or Licensed Premises under the power of eminent domain: (i) Licensor shall not have any obligation to repair or restore the Licensed Premises or any alterations or personal
property; (ii) Licensee shall be entitled only to a proportionate abatement of the License Fee during the time and to the extent the Licensed Premises are unfit for the purposes permitted under this Agreement and not used by Licensee as a
result thereof; (iii) Licensee shall not, by reason thereof, have a right to terminate this Agreement unless the Lease shall be terminated; and (iv) Licensor and Landlord reserve the right to terminate this Agreement in connection with any
right granted to either Licensor or Landlord under the Lease whether or not the Licensed Premises is damaged or the subject of a taking. In the event Licensor or Landlord exercises the right to terminate the Lease as the result of any such fire,
casualty or taking, (a) Licensor shall provide Licensee with a copy of the relevant termination notice and this Agreement shall terminate on the date upon which the Lease terminates and (b) Licensee shall immediately pay to Licensor all of
Licensee’s insurance proceeds relating to all alterations (but not to Licensee’s personal property). 

  

	10.	 Limit of Liability. Notwithstanding anything to the contrary contained in this Agreement, Landlord,
Licensor, their respective, members, officers, directors, employees, agents, servants, lenders, mortgagees, ground lessors beneficiaries and contractors (collectively, the “Licensor Parties”), shall not be liable for any
damages or injury to person or property or resulting from the loss of use thereof sustained by Licensee or anyone having claims through or on behalf of Licensee, based on, arising out of, or resulting from, any cause whatsoever, including any due to
the Building becoming out of repair, or due to the occurrence of any accident or event in or about the Building, or due to any act or neglect of any tenant or occupant of the Building or any other person. Notwithstanding the foregoing provision of
this Section, Licensor Parties shall not be released from liability to Licensee for any physical injury to any natural person caused by Licensor Parties’ gross negligence or willful misconduct to the extent such injury is not covered by
insurance either carried by Licensee (or such person) or required by this Agreement to be carried by Licensee; provided that Licensor Parties shall not, under any circumstances, be liable for any exemplary, punitive, consequential or indirect
damages (or for any interruption of or loss to business). 

  

	11.	 Waiver of Claims. Licensee hereby releases and waives any and all claims against the Licensor Parties
for injury or damage to person, property or business of every kind, nature and description, sustained in or about the Building or the Licensed Premises by Licensee or anyone claiming under Licensee, other than by reason of gross negligence or
willful misconduct of the Licensor Parties and except in any case which would render this release and waiver void under applicable law. 

  
 6 

	12.	 Insurance. See Insurance Requirements attached hereto as Exhibit 3. 

 

	 	(a)	 Subrogation. Licensee and its insurers hereby waive any and all rights of recovery or subrogation
against the Licensor Parties with respect to any Claims (as defined below) howsoever caused, that are covered, or should have been covered, by valid and collectible insurance, including any deductibles or self-insurance maintained thereunder. If
necessary, Licensee agrees to endorse the required insurance policies to permit waivers of subrogation as required hereunder and hold harmless and indemnify the Licensor Parties for any loss or expense incurred as a result of a failure to obtain
such waivers of subrogation from insurers. Such waivers shall continue so long as Licensee’s insurers so permit. Any termination of such a waiver shall be by written notice to Licensor. Licensee, upon obtaining the policies of insurance
required or permitted hereunder, shall give notice to its insurance carriers that the foregoing waiver of subrogation is contained in herein. If such policies shall not be obtainable with such waiver or shall be so obtainable only at a premium over
that chargeable without such waiver, then Licensee shall notify Licensor of such conditions. 

  

	 	(b)	 Assumption of Risk. Licensee assumes the risk of damage, and shall be liable for any damage caused to,
any fixtures, goods, inventory, merchandise, equipment and leasehold improvements, and the Licensor Parties shall not be liable for injury to Licensee’s business or any loss of income therefrom, relative to such damage. Licensee shall, at
Licensee’s sole cost and expense, carry such insurance as Licensee desires for Licensee’s protection with respect to personal property of Licensee or business interruption. 

 

	13.	 Indemnification. Licensee shall indemnify, defend (by counsel acceptable to Licensor), release, protect
and hold the Licensor Parties harmless from and against any and all demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages, suits or judgments, and all reasonable expenses (including reasonable attorneys’
fees, charges and disbursements, regardless of whether the applicable demand, claim, action, cause of action or suit is voluntarily withdrawn or dismissed) incurred in investigating or resisting the same (collectively, “Claims”) of
any kind or nature that arise before, during or after the Term, arising out of or related to: (i) the use or occupancy of the Licensed Premises or Shared Premises by Licensee or its Occupants or anyone claiming by, through or under Licensee;
(ii) the failure by Licensee or anyone claiming by, through or under Licensee to comply with any term, condition, or covenant of this Agreement or the Lease, including, without limitation, Licensee’s obligation to surrender the Licensed
Premises in the condition herein required; (iii) the negligence or willful misconduct of Licensee, its agents or anyone claiming by, through or under Licensee; (iv) the existence of Hazardous Materials on, under or about the Licensed
Premises to the extent caused, stored, released, discharged or introduced by Licensee or its agents; (v) the death of or injury to any person or damage to any property in the Licensed Premises; or (vi) the death of or injury to any person
or damage to any property on or about the Building to the extent caused by the negligence, recklessness or willful misconduct of Licensee or its agents. Notwithstanding the foregoing, Licensee shall not, under any circumstances, be liable for any
exemplary, punitive, consequential or indirect damages (or for any interruption of or loss to business), except as set forth in Section 2(b). 

  
 7 

	14.	 Assignment. 

  

	 	(a)	 No Assignment. Licensee shall not assign, encumber or transfer this Agreement, or any part of it, or its
right or interest in it, without Licensor’s prior written approval, which shall not be unreasonably conditioned, withheld, or delayed. Notwithstanding the foregoing, Licensee may sublicense or assign this Agreement to its affiliates,
subsidiaries or successors resulting from an acquisition, merger, spin-off or consolidation (“Related Party) provided that: (a) Licensee gives Licensor at least thirty (30) days’ advanced
written notice and (b) Licensee remains liable for its obligations hereunder. Licensee shall not in any way obstruct or interfere with the rights of other licensees, occupants or users of the Building, nor shall it permit its employees,
representatives, or contractors to do so. Licensor may assign this Agreement. 

  

	 	(b)	 Prohibited Transfers. Notwithstanding any other provision contained in this Agreement to the contrary,
Licensee shall not knowingly, after reasonable inquiry, transfer or permit the transfer of any legal or beneficial interest in Licensee to, or assign, sublicense or otherwise transfer all or any portion of its interest under this Agreement or in all
or any portion of the Licensed Premises to, or enter into any sublicense or other use or occupancy agreement to, any: 

  

	 	i.	 Person (or any Person whose operations are directed or controlled by a Person) that has been convicted of or
has pleaded guilty in a criminal proceeding to a felony or that is an ongoing target of a grand jury investigation convened pursuant to applicable statutes concerning organized crime; 

 

	 	ii.	 Person organized in or controlled from a country, the activities with respect to which are regulated or
controlled pursuant to the following laws and the regulations or executive orders promulgated thereunder: (A) the Trading with the Enemy Act of 1917, 50 U.S.C. App. §1, et seq., as amended; (B) the International Emergency
Economic Powers Act of 1976, 50 U.S.C. §1701, et seq., as amended; or (C) the Anti-Terrorism and Arms Export Amendments Act of 1989, codified at Section 6(j) of the Export Administration Act of 1979, 50 U.S.C. App. §2405W,
as amended; or 

  

	 	iii.	 Person with whom Landlord or Licensor is restricted from doing business under either (A) Executive Order
No. 13224 on Terrorist Financing (effective September 24, 2001 (as amended or supplemented from time to time, the “Executive Order”), or (B) the Uniting and Strengthening America by Providing Appropriate Tools Required to
Intercept and Obstruct Terrorism Act of 2001 (Public Law 10756; as amended, from time to time, the “Patriot Act”), or (C) the regulations of the United Stated Department of the Treasury Office of Foreign Assets Control
(including, without limitation, those Persons named on the list of “Specially Designated Nationals and Blocked Persons” as modified from time to time), or other governmental action; or 

 

	 	iv.	 Affiliate of any of the Persons described in the preceding paragraphs (i), (ii) or (iii).

 As used herein, “Person” shall mean any individual or entity, and the heirs, executors, administrators, legal
representatives, successors and assigns of such Person where the context so admits; “Affiliate” shall mean, with respect to any Person, (i) in the case of any such Person which is an Entity, any partner, shareholder,

  
 8 

 
member or other owner of such Entity, provided that such partner, shareholder, member or other owner owns more than fifty percent (50%) of the Equity Interests of such Entity, and (ii) any
other Person which is a Parent, a Subsidiary, or a Subsidiary of a Parent with respect to such Person or with respect to one or more of the Persons referred to in the preceding clause (i); “Equity Interest” shall mean with respect to any
Entity, (i) the legal (other than as a nominee) or beneficial ownership of outstanding voting or non-voting stock of such Entity if such Entity is a business corporation, a real estate investment trust or
a similar entity, (ii) the legal (other than as a nominee) or beneficial ownership of any partnership, membership or other voting or non-voting ownership interest in a partnership, joint venture, limited
liability company or similar entity, (iii) a legal (other than as a nominee) or beneficial voting or non-voting interest in a trust if such Entity is a trust and (iv) any other voting or nonvoting
interest that is the functional equivalent of any of the foregoing; “Parent” shall mean, with respect to any Subsidiary, any Person which owns directly or indirectly through one or more Subsidiaries the entire Equity Interest in such
Subsidiary; and “Subsidiary” shall mean, with respect to any Parent, any Entity in which a Person owns, directly or indirectly through one or more Subsidiaries, the entire Equity Interest in such Subsidiary. 

 

	15.	 Miscellaneous. 

 

	 	(a)	 Signage. Licensor, at its sole cost, shall provide building standard signage on all tenant directories
at the Building as well as at the entrance to the Licensed Premises, to the extent permitted under the terms of the Lease. 

  

	 	(b)	 Attorneys’ Fees. In the event of any litigation or arbitration between Licensee and Licensor,
whether based on contract, tort or other cause of action or involving bankruptcy or similar proceedings, in any way related to this Agreement, the non-prevailing party shall pay to the prevailing party all
reasonable attorneys’ fees and costs and expenses of any type, without restriction by statute, court rule or otherwise, incurred by the prevailing party in connection with any action or proceeding (including arbitration proceedings, any appeals
and the enforcement of any judgment or award), whether or not the dispute is litigated or prosecuted to final judgment. The “prevailing party” shall be determined based upon an assessment of which party’s major arguments or positions
taken in the action or proceeding could fairly be said to have prevailed (whether by compromise, settlement, abandonment by other party of its claim or defense, final decision after any appeals, or otherwise) over the other party’s major
arguments or positions on major disputed issues. Any fees and cost incurred in enforcing a judgment shall be recoverable separately from any other amount included in the judgment and shall survive and not be merged in the judgment.

  

	 	(c)	 Authority. Each person executing this Agreement on behalf of a party hereto represents and warrants that
he or she is authorized and empowered to do so and to thereby bind the party on whose behalf he or she is signing. 

  

	 	(d)	 Brokerage. Licensee warrants and represents that Licensee has dealt with no broker in connection with
the consummation of this Agreement other than CBRE (“Broker”), and, in the event of any brokerage claims against Licensor predicated upon prior dealings with Licensee, Licensee agrees to defend the same and indemnify Licensor
against any such claim (except any claim by Broker). 

  

	 	(e)	 Captions. All captions and headings in this Agreement are for the purposes of reference and convenience
and shall not limit or expand the provisions of this Agreement. 

  
 9 

	 	(f)	 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be
deemed to be an original and all of which taken together shall comprise but a single instrument. 

  

	 	(g)	 Entire Agreement. This Agreement contains all of the covenants, conditions and agreements between the
parties concerning the Licensed Premises, and shall supersede any and all prior correspondence, agreements and understandings concerning the Licensed Premises, both oral and written. No addition or modification of any term or provision of this
Agreement shall be effective unless set forth in writing and signed by both Licensor and Licensee. 

  

	 	(h)	 Notices. Any notice required or permitted under this Agreement shall be effective if in writing and
delivered to the other party at the following address. 

  

			
	MIL 40G, LLC	  	Yumanity Therapeutics, Inc.
	40 Guest Street	  	790 Memorial Drive, #2C
	Brighton, MA 02135	  	Cambridge, MA 02139
	Attn: Amrit Chaudhuri	  	 Attn: Paulash Mohsen
  

		  	After occupancy of the Licensed Premises:
		  	40 Guest Street
		  	Brighton, MA 02135
		  	Attn: Paulash Mohsen

  

	 	(i)	 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts. Licensee hereby consents to the personal jurisdiction and venue of any state or federal court located in Suffolk County Massachusetts, and any successor court, and the service or process by any means authorized by such
court. 

  

	 	(j)	 Exhibits. All exhibits and any schedules or riders attached to this Agreement are incorporated herein by
this reference and made a part hereof, and any reference in the body of the Agreement or in the exhibits, schedules or riders to the Agreement shall mean this Agreement, together with all exhibits, schedules and riders. 

 

	 	(k)	 Waiver of Trial by Jury. LICENSEE HEREBY WAIVES ANY AND ALL RIGHTS IT MAY HAVE UNDER APPLICABLE LAW TO
TRIAL BY JURY WITH RESPECT TO ANY DISPUTE WITH ANY LICENSOR PARTIES ARISING DIRECTLY OR INDIRECTLY IN CONNECTION WITH THIS AGREEMENT OR THE LICENSED PREMISES. NOTHING CONTAINED IN THIS SECTION SHALL BE CONSTRUED AS A WAIVER BY LICENSOR OR LANDLORD
OF ANY OF ITS RIGHTS TO TRIAL BY JURY IN CONNECTION WITH THE LEASE OR THIS AGREEMENT FOR ANY CLAIMS OR CAUSES OF ACTION SO TRIABLE. 

  

	 	(l)	 Successors and Assigns. Subject to the provisions of this Agreement relating to assignment and
subletting, this Agreement shall be binding upon, and shall inure to the benefit of the parties’ respective representatives, successors and assigns. 

  
 10 

	 	(m)	 Relationship of Parties. Nothing in this Agreement shall be deemed to create any joint venture or
principal-agent relationship or partnership between any of the parties hereto, and no party is authorized to, and no party shall, act toward third parties or the public in any manner that would indicate any such relationship. 

 

	 	(n)	 Access. Landlord and Licensor reserve the right to enter the Licensed Premises upon reasonable prior
written or oral notice to Licensee (except that in case of emergency no notice shall be necessary) in order to inspect the Licensed Premises and/or the performance by Licensee of the terms of this Agreement or to exercise Licensor’s rights or
perform Licensor’s obligations hereunder. 

 LICENSEE UNDERSTANDS AND ACKNOWLEDGES THAT RIGHTS UNDER THIS AGREEMENT ONLY
CONSTITUTE A LICENSE FOR USE OF THE LICENSED PREMISES AND DO NOT INVOLVE THE GRANT OF ANY INTEREST IN REAL ESTATE. LICENSEE SPECIFICALLY DISCLAIMS ANY RIGHTS TO SUMMARY PROCESS AND, PROVIDED THAT LICENSOR COMPLIES WITH ALL OBLIGATIONS (INCLUDING
WITHOUT LIMITATION NOTICE AND CURE REQUIREMENTS) HEREUNDER, EXPLICITLY PERMITS LICENSOR TO USE SELF-HELP REMEDIES PROVIDED THAT SUCH SELF-HELP REMEDIES DO NOT BREACH THE PEACE. 

IN WITNESS WHEREOF, Licensor and Licensee have duly executed this Agreement as of the day and year first above written. 

 

							
	MIL 40G, LLC	 		  	Yumanity Therapeutics, Inc.	  	
				
	 /s/ Amrit Chaudhuri
	 		  	 /s/ Paulash Mohsen
	  	
	By: Amrit Chaudhari	 		  	By: Paulash Mohsen	  	
	Title: CEO	 		  	Title: Chief Business Officer	  	

  
 11 

 Exhibit 1: Licensed Premises 

 
 

 

  
 Exhibit 1 

 Exhibit 2: Service Agreement 

Emergency Procedures: A copy of 40 Guest Street emergency procedures will be provided at the start of occupancy. 

 

					
	Licensee Space	  	Laboratory Space	  	 Laboratories can be equipped with fume hoods, central lines for carbon dioxide gas and nitrogen gas, and heavy electrical and exhaust
infrastructure.
  
 Gases and chemicals provided by Licensor:

1.  Vacuum
  

2.  Carbon dioxide gas
  

3.  Nitrogen gas
  

4.  Other gases available upon request and may incur additional fees

 
 5.  Dry ice

 
 6.  Liquid Nitrogen

 
 Equipment provided may include:

 
 1.  Private BSL-1 wet lab benches, sink, eye-wash, and safety shower
  

2.  Private BSL-2 cell/tissue culture-capable room with wet lab
benches, sink, eye-wash, and safety shower
  

3.  Six (6) 8-foot chemical fume hoods and two (2) 6-foot chemical fume hoods with solvent storage
  

4.  Forty-eight (48) lab benches

 
 Licensee must assign a Laboratory Supervisor and an EHS contact person.

	  	  
 Offices
	  	  
 Offices are connected to or located near the laboratory space.
Additional office space may be licensed for an additional fee depending on availability.
  

Licensor will provide Licensee furniture:
  

•  66 Sit-to-stand
desks
  
 •  66 Ergonomic
chairs
  
 •  66 Filing
pedestals
  
 Licensor is not obligated to provide additional furniture except as
expressly set forth herein.

	  	  
 IT
	  	  
 Suites have a private virtual network with access to redundant
gigabyte Internet service and private Wi-Fi covering Licensed Premises.

	  	  
 Auxiliary Rooms
	  	  
 Suites may have private auxiliary rooms for sample storage,
instruments, equipment, tissue culture, etc.

  
 Exhibit 2 

					
			
		  	Security	  	Each suite is secured key card accessible. Building entrances and common areas are monitored by video surveillance.
			
		  	Emergency Power	  	 Emergency generators that support critical equipment and base building life safety equipment are operated by the facility manager together
with outside support.
  
 Licensee may need to provide its own Uninterrupted Power
Supply (UPS) for equipment.

	Common Space	  	Conference Room	  	 Conference rooms will be made available with a central internet-based reservation system. AV equipment is provided or available for each
conference room.
  
 Conference call equipment will be available in all conference
rooms. International calls are available on request with at least 24-hour notice.
  

	  	Lecture Room	  	 A lecture room is available for seminars, lectures, and large meetings. The lecture room requires an advanced reservation and a nominal fee
may be charged for set up and cleaning services.
  
 Licensor may offer a range of
events, seminars and lectures free of charge for Licensees. Third-party seminars and training may also be provided at a nominal cost.
  

	  	Interactive Space	  	 Coffee, tea, water, and snacks will be available in this space.

 

	  	Showers	  	 Showers are available to Licensee.
  

	  	Wellness Room	  	 A Wellness Room is available on each floor upon request. Wellness rooms will be made available with a central internet-based reservation
system
  

	  	Wifi	  	 Public wifi is available on the 3rd and 4th floor.
  

			
	IT	  	Support	  	 Tier 1 tech support will be provided by Licensor in collaboration with a third-party vendor. Tier 3 tech support will be performed on an
ongoing basis for the common IT infrastructure environment.
  

	  	Network	  	 Licensee will have access to Licensors network. All of Licensor’s network hardware is protected by UPS.

 
 Scaling Suite Licensees may install and house their own networking and server equipment.
Licensee will need ability to setup VLAN for WiFi and private firewall after Licensor’s firewall. Additional requirements may apply. A detailed description of Network and IT Services is available upon request.

 

	  	Wi-Fi	  	Public wifi is available on the 3rd and 4th floor

  
 Exhibit 2 

					
	Operational Support	  	Facility	  	 On-site facility support staff will be available to Licensee during normal business hours.

 
 Basic personal protective equipment (PPE) (lab coats, gloves, safety glasses, etc.) for
general use will be available. Specialty PPE must be provided by the Licensee.
  

Janitorial services will be provided on a schedule based on the needs of the Licensee.

 

	  	Permits	  	 The following permits have been obtained by the Licensor for the Licensed Premises*:

 
 •  Wastewater disposal

 
 •  Flammable liquids and
solvents
  
 •  Licensor will
own the EPA ID number.
  

•  Biosafety and/or rDNA permits for small scale work at BSL1 or BSL2 containment.

 
 Licensor shall use best efforts to ensure each of these permits are
renewed or otherwise maintained in a manner to remain in effect throughout the Term.
  

* Biosafety and/or rDNA permits may need to be obtained by the Licensee

		  	  
 EHS
	  	  
 During the application process, Licensee must complete a Hazard
Assessment Form that addresses the type and amount of chemicals and biological agents that the Licensee plans to use in the Licensed Premises. No work may be conducted in the Licensed Premises until the form is approved by Licensor, which approval
not to be unreasonably withheld, conditioned, or delayed. Based on this assessment, the Licensor will create SOP’s and EHS training requirements for the Licensee: Licensor will use commercially reasonable efforts to incorporate Licensee’s
input into such SOP’s and EHS training requirements. Additional permits may need to be obtained by the Licensee.
  

A hard copy of all safety and emergency procedures will be delivered to the Licensee and, in addition, will be available on each floor. Recommendations for EHS
must be followed by the Licensee. Licensor will conduct a mandatory meeting with designees of the Licensee to communicate and discuss all relevant emergency information and policies.

 
 Only Biosafety Level 1 and 2 work is allowed in Licensed Premises. All Biosafety
Level 1 and 2 work must be approved by the SmartLabs Institutional Biosafety Committee (IBC). No select agent work is allowed. Depending on the biosafety work, it may need to be reviewed either by the City of Boston’s Boston Public Health
Commission or the SmartLabs Institutional Biosafety Committee.
  
 Licensor, its agents
and employees shall, prior to entering the Licensed Premises, have received all necessary- training in Biosafety Level 1 and 2 protocol.

  
 Exhibit 2 

					
	Operational Support (Cont.)	  	Glasswash and Autoclave	  	 A glasswash and autoclave facility will be available to Licensee, provided that such facilities will be run by Licensor and/or a third-party
(i.e. Licensee shall not run these systems).
  

	  	EHSS Training	  	 Training is provided for all Licensee staff. Initial training will consist of a walk-through of die Licensed Premises and both in-person and web-based training and certifications.
  

Ongoing training is web-based and Licensor will keep a training record of all training received by Licensee staff.
Failure to complete training may result in removal of access or work stoppage.
  

Training provided covers the following topics:
  

•  Accident Reporting
  

•  Emergency Action Plan
  

•  PPE/Job Hazard Analysis
  

•  Respiratory Protection
  

•  Blood Borne Pathogens
  

•  Biosafety
  

•  Formaldehyde
  

•  Hazard Communication
  

•  Chemical Hygiene
  

•  Waste Handling
  

•  Eye Protection and Safety
  

•  Fire Safety Prevention/Fire Extinguishers

 
 •  First Aid and Emergency
Response
  
 •  Sharps Safety
and Needle-Stick Prevention
  

•  Emergency Action Plan
  

In addition to the standard training offered, Licensor has developed template SOP’s for Particularly Hazardous Substances. Licensee may work with the
Licensor’s EHS team to develop SOPs for Lab-Specific Procedures or Substances, which can be used for lab-specific (or process specific) training. Licensee is
responsible for providing these types of training to its employees.
  
 *Additional
specialized training may be required.
  

	  	EHS Training Audits	  	 Licensor or a third-party will conduct EHS audits for all procedures and equipment and Licensee will implement corrective actions at a
frequency required by federal, state, and local regulations. A review of Standard Operating Procedures will be provided when requested, at the Licensee’s cost.

 

  
 Exhibit 2 

					
		  	Inspections	  	 Emergency equipment such as safety showers, eyewash stations, fire extinguishers and emergency egress, will be checked by Licensor or a third
part}’ on a regular basis as required by EHS provisions. Chemical fume hoods will be inspected and certified on a yearly basis.
  

Licensee is responsible for the yearly certification and inspections of biosafety cabinets and all other private equipment.

 

		  	Waste Management	  	 Licensor will manage, maintain, and operate the pH neutralization system for the Premises, which Licensor may accomplish by having a
third-part}’ vendor manage all aspects of wastewater management. A wastewater operator will service and maintain the pH neutralization system and check all auxiliary piping, etc. Preventative maintenance of all wastewater systems will be done
once per month. Wastewater sampling, sample transport, analysis and reports will be done by a third-party’ vendor. The chart recorder and other data logs will be checked regularly and available to Licensee upon request. Licensor will remedy any
disruption on wastewater systems and shall use commercially reasonable efforts to avoid interference with Licensee’s ongoing work. If needed, Licensor will collect and ship wastewater as appropriate to prevent or resolve any disruption.

 
 Hazardous, non-hazardous and biological waste
will be removed from satellite accumulation areas in the Licensed Premises such as laboratories, hoods or storage rooms. To ensure ongoing compliance, improvements of existing systems will be based on third-part}’ recommendations. Licensor will
maintain a wastewater treatment license.
  

		  	Purchasing	  	 Licensor will maintain a central inventory system for chemicals, flammable solvents and toxic biologicals, including MSDS administration and
centralized receiving. Licensee will be responsible for ordering chemicals and biologicals and will bear sole responsibility and cost of any errors and costs associated with shipment: or instances where chemicals or biologicals are not in compliance
with the rules and regulations governing the Licensed Premises and must be returned or properly disposed of.
  

		  	Emergencies	  	There will be 24/7 on-call emergency personnel in case of emergencies such as accidents, spills, etc.

  
 Exhibit 2 

					
	Office Support	  	Mail	  	 Standard receiving, logistics, handling and mail delivery services are provided by the Licensor. Specialized products, instrumentation
(especially when heavy), chemicals, biologicals and regulated products that require special handing will require Licensee to obtain approvals and make special arrangements to support the necessary’ logistics and handling.

 

	  	Print and Copy	  	 Shared access printers and copiers for standard print and copy jobs will be maintained by Licensor. Notwithstanding the foregoing, Licensee
may, at its discretion, operate one or more dedicated printers for use by Licensee in the Licensed Premises. Licensee will be responsible for the procurement and maintenance of any dedicated printers.

 

	Security	  	Secured Space	  	 Licensor’s staff will be available at the reception desk Monday- Friday from 8am to 5pm. After business hours, security’ personnel
remain on-site. Licensee can request that security personnel make tours of Licensed Premises after hours. Biosafety’ regulations may prevent security’ personnel from entering Licensed Premises.
Excepting emergencies, Licensee shall have access to the building 365 days per year and 24 hours per day.
  

	  	Visitors	  	 All visitors must sign in at reception. Licensee is responsible for meeting the visitor at the reception and escorting the visitor within the
Building and Licensed Premises. Due to safety concerns, visitors will not be allowed into Licensed Premises without prior approval by Licensor.
  

Licensee is solely responsible for its visitors’ actions, ensuring its visitors adhere to all of Licensor’s policies, and for accompanying visitors
at all times for the duration of their visit. See Visitor Policy for more details.

 The following services are not provided and/or are not included in License. When available, these services can be provided
under a separate agreement with different terms. 
 Scaling Suites 

Renovations past 365 days of commencement date. 
 IT Support
Level 2 and 4 
 Any research/work required to be conducted under Biosafety Levels (BSL) 3 or 4 policies and guidelines. 

Use of any radioactive material. 
 Radiation producing equipment
(including lasers) will need special approval 
 Shared tissue culture rooms 

Specific Training such as RCRA, DOT, cyanide, etc. 
 Exclusive use
of shared and common spaces 
 Special PPE 
 International Phone
Calls in Conference Rooms (available upon request and with 24-hour prior notice) 
 Shipping of Packages 

  
 Exhibit 2 

 Costs of moving in and moving out 

Certification and Preventative Maintenance of company owned equipment 

Use of Licensor’s accounts for purchases 

  
 Exhibit 2 

 Exhibit 3: Insurance Requirements 

 

	1.	 Insurance. 

1.1. Licensee shall, at its own cost and expense, procure and maintain during the Term the following insurance for the benefit of Licensee and
Landlord (as their interests may appear) with insurers financially acceptable and lawfully authorized to do business in the state where the Licensed Premises are located: 

(a) Commercial General Liability insurance on a broad-based occurrence coverage form, with coverages including but not limited to bodily injury
(including death), property damage (including loss of use resulting therefrom), premises/operations, personal and advertising injury, and contractual liability with limits of liability of not less than $2,000,000 for bodily injury and property
damage per occurrence, $2,000,000 general aggregate, which limits may be met by use of excess and/or umbrella liability insurance provided that such coverage is at least as broad as the primary coverages required herein. 

(b) Commercial Automobile Liability insurance covering liability arising from the use or operation of any vehicle, including those owned, hired
or otherwise operated or used by or on behalf of Licensee. The coverage shall be on a broad-based occurrence form with combined single limits of not less than $1,000,000 per accident for bodily injury and property damage. 

(c) Commercial Property insurance covering property damage to the full replacement cost value and business interruption. Covered property shall
include all of Licensee’s improvements in the Licensed Premises and Licensee’s property including personal property, furniture, fixtures, machinery, equipment, stock, inventory and improvements and betterments, which may be owned by
Licensee or Licensor and required to be insured hereunder, or which may be leased, rented, borrowed or in the care custody or control of Licensee, or Licensee’s agents, employees or subcontractors. Such insurance shall be written on an
“all risk” of physical loss or damage basis including the perils of fire, extended coverage, electrical injury, mechanical breakdown, windstorm, vandalism, malicious mischief, sprinkler leakage,
back-up of sewers or drains, flood, earthquake, terrorism and such other risks Licensor may from time to time designate, for the full replacement cost value of the covered items with an agreed amount
endorsement with no co-insurance. Business interruption coverage shall have limits sufficient to cover Licensee’s lost profits and necessary continuing expenses, including License Fees due Licensor under
the Agreement. The minimum period of indemnity for business interruption coverage shall be twelve (12) months. 
 (d) Workers’
Compensation insurance as is required by statute or law, or as may be available on a voluntary basis and Employers’ Liability insurance with limits of not less than the following: each accident, Five Hundred Thousand Dollars ($500,000); disease
($500,000); disease (each employee), Five Hundred Thousand Dollars ($500,000). 
 (e) Intentionally omitted. 

(f) Pollution Legal Liability insurance is required if Licensee stores, handles, generates or treats Hazardous Materials, as determined solely
by Licensor, on or about the Licensed Premises. Such coverage shall include bodily injury, sickness, disease, death or mental anguish or shock sustained by any person; property damage including physical injury to or destruction of tangible property
including the resulting loss of use thereof, clean-up costs, and the loss of use of tangible property that has not been physically injured or destroyed; and defense costs, charges and expenses incurred in the
investigation, adjustment or defense of claims for such compensatory damages. Coverage shall apply to both sudden and non-sudden pollution conditions including the discharge, dispersal, release or escape of
smoke, vapors, soot, fumes, acids, alkalis, toxic chemicals, liquids or gases, waste materials or other 

  
 Exhibit 3 

 
irritants, contaminants or pollutants into or upon land, the atmosphere or any watercourse or body of water. Claims-made coverage is permitted, provided the policy retroactive date is
continuously maintained prior to the commencement date of this agreement, and coverage is continuously maintained during all periods in which Licensee occupies the Licensed Premises. Coverage shall be maintained with limits of not less than
$1,000,000 per incident with a $2,000,000 policy aggregate and for a period of two (2) years thereafter. 
 1.2. The insurance required
of Licensee shall be with companies at all times having a current rating of not less than A- and financial category rating of at least Class VII in “A.M. Best’s Insurance Guide” current
edition. Licensee shall obtain for Licensor from the insurance companies/broker or cause the insurance companies/broker to furnish certificates of insurance evidencing all coverages required herein to Licensor. Licensor reserves the right to require
complete, certified copies of all required insurance policies including any endorsements. No such policy shall be cancelable or subject to reduction of coverage or other modification or cancellation except after twenty (20) days’ prior
written notice to Licensor from Licensee or its insurers (except in the event of non-payment of premium, in which case ten (10) days’ written notice shall be given). All such policies shall be
written as primary policies, not contributing with and not in excess of the coverage that Licensor may carry. Licensee shall, at least ten (10) days prior to the expiration of such policies, furnish Licensor with renewal certificates of
insurance or binders. Licensee agrees that if Licensee does not take out and maintain such insurance, Licensor may (but shall not be required to) procure such insurance on Licensee’s behalf and at its cost to be paid by Licensee as part of its
License Fee. Commercial General Liability, Commercial Automobile Liability, Umbrella Liability and Pollution Legal Liability insurance as required above shall name Licensor, Landlord, and their respective officers, employees, agents, general
partners, members, subsidiaries, affiliates and Lenders (“Landlord Parties”) as additional insureds as respects liability arising from work or operations performed by or on behalf of Licensee, Licensee’s use or occupancy of the
Licensed Premises, and ownership, maintenance or use of vehicles by or on behalf of Licensee. 
 1.3. In each instance where insurance is to
name Landlord Parties as additional insureds, Licensee shall, upon Licensor’s written request, also designate and furnish certificates evidencing such Landlord Parties as additional insureds to (a) any lender of Licensor or Landlord
holding a security interest in the Building, (b) the landlord under any lease whereunder Landlord is a tenant of the real property upon which the Licensed Premises is located if the interest of Landlord is or shall become that of a tenant under
a ground lease rather than that of a fee owner and (c) any management company retained by Licensor or Landlord to manage the Building. 

1.4. Except to the extent caused by the Landlord Parties, Licensee assumes the risk of damage to any fixtures, goods, inventory, merchandise,
equipment and leasehold improvements, and Licensor and Landlord shall not be liable for injury to Licensee’s business or any loss of income therefrom, relative to such damage, all as more particularly set forth within the Agreement. Licensee
shall, at Licensee’s sole cost and expense, carry such insurance as Licensee desires for Licensee’s protection with respect to personal property of Licensee or business interruption. 

1.5. Licensee and its insurers hereby waive any and all rights of recovery against the Landlord Parties with respect to any loss, damage,
claims, suits or demands, howsoever caused, that are covered, or should have been covered, by valid and collectible workers’ compensation, employer’s liability, and other liability insurance required to be carried by Licensee pursuant to
this Exhibit 3, including any deductibles or self-insurance maintained thereunder. If necessary, Licensee agrees to endorse the required workers’ compensation, employer’s liability and other liability insurance policies to permit
waivers of subrogation as required hereunder and hold harmless and indemnify the Landlord Parties for any loss or expense incurred as a result of a failure to obtain such waivers of subrogation from insurers. Such waivers shall continue so long as
Licensee’s insurers so permit. Any termination of such a waiver shall be by written notice to Licensor, containing a description of the circumstances hereinafter set forth in this Exhibit 3.

  
 Exhibit 3 

 
Licensee, upon obtaining the policies of workers’ compensation, employer’s liability and other liability insurance required or permitted under this Exhibit 3, shall give notice
to its insurance carriers that the foregoing waiver of subrogation is contained in this Exhibit 3. If such policies shall not be obtainable with such waiver or shall be so obtainable only at a premium over that chargeable without such waiver,
then Licensee shall notify Licensor of such conditions. 
 1.6. Licensor may require insurance policy limits required under the Agreement to
be raised to conform with requirements of Landlord’s or Licensor’s lender. 
 1.7. The provisions of this Exhibit 3 shall
survive the expiration or earlier termination of the Agreement. 

  
 Exhibit 3 

 Exhibit 4 
  

 

  
 Exhibit 4 

 

 

  
 Exhibit 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]